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ABSTRACT 
 
Introduction and aims 
Despite the ongoing global tuberculosis (TB) problem and extensive research into 
protective immunity against this intracellular pathogen, mechanisms of protective 
immunity against Mycobacterium tuberculosis (Mtb) in humans have not been fully 
clarified. Numerous reports have addressed the potential immunological defect(s) in 
infected individuals that have developed active TB in comparison to those who have 
remained healthy in spite of infection. Markers of treatment response phenotypes are 
still elusive. The aims of this study were to define lymphocyte subsets in the 
peripheral blood of TB patients and controls, to determine intracellular interferon-γ 
(IFN-γ) and interleukin-4 (IL-4) production and to find correlations of these data 
with microbiologically-defined treatment response. 
Methods 
Whole blood tests were done on 30 HIV-negative, smear-positive pulmonary TB 
patients and 18 healthy skin test positive volunteers resident in the same community. 
Immunophenotyping was performed by flow cytometry, combined with routine 
haematology, for the enumeration of peripheral blood immune cell subtypes. Whole 
blood was also stimulated in vitro with anti-CD3 monoclonal antibody and 
intracellular IFN-γ and IL-4 determined by flow cytometry. Lymphocyte 
proliferation in response to heat-killed Mtb was determined by tritiated thymidine 
incorporation. Routine microbiological monitoring by sputum smears and culture 
was done throughout the patients’ 26 weeks of treatment.  
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Results 
Compared to healthy controls, absolute numbers of peripheral blood lymphocytes 
and lymphocyte subsets were significantly depressed in patients at diagnosis but 
normalized during treatment with the exception of natural killer (NK) cells and 
natural killer T (NKT) cells. A novel subset of the latter was found to correlate 
significantly with treatment response. IFN-γ-producing T cells after a 4-hour T cell 
receptor stimulation were significantly higher in patients at diagnosis and normalized 
during treatment. Supplementary kinetic experiments showed that IFN-γ production 
in patients at diagnosis seemed to be accelerated. Lymphocyte proliferation was 
lower in patients at diagnosis and normalized during treatment. Neither IFN-γ 
production nor lymphocyte proliferation correlated with treatment response. Low 
intracellular IL-4 production was constitutive in patients and controls, was 
insignificantly lower in patients at diagnosis than in controls and, in the slow 
responder patient group, it was significantly lower than in the fast responder group. 
High IL-4 expression was found in low numbers of T cells in patients and controls 
and supplementary experiments showed co-expression of active caspase-3 in these 
cells, which signified apoptosis. 
Conclusions 
Lymphocyte subset phenotypes associated with TB are largely abnormal only during 
active infection and only a novel subset of NKT cells showed correlation with 
treatment response. Intracellular IFN-γ production and lymphocyte proliferation is 
increased and decreased, respectively, only during active infection and does not 
correlate with treatment response. The T helper 1/T helper 2 (Th1/Th2) hypothesis 
could not be confirmed in the context of tuberculosis but instead constitutive IL-4 
production may play a role as a growth factor.  
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ABSTRAK 
 
Inleiding en Doelwit 
Tenspyte van die wêreldwye tuberkulose (TB) probleem en ekstensiewe navorsing in 
die veld van beskermende immuniteit teen Mycobacterium tuberculosis (Mtb), is die 
menslike meganisme(s) van beskermende immuniteit teen hierdie intrasellulêre 
patogeen nog nie duidelik nie. Verskeie verslae adresseer die potensïele 
immunologiese defek(te) in geïnfekteerde individue met aktiewe TB, in teenstelling 
met individue wat gesond bly tenspyte van infeksie. Geen definitiewe fenotipiese 
merkers wat uitkoms van behandeling kan voorspel is nog bekend nie. Die doelwitte 
van hierdie studie was om limfosiet subgroepe te defineer in TB pasiënte en in 
kontroles, om intrasellulêre interferon-γ (IFN-γ) en interleukien-4 (IL-4) produksie te 
bepaal en om korrelasies van hierdie data met mikrobiologies defineerde 
behandelingsresponse te vind. 
Metodes 
Heel-bloed toetse is gedoen op 30 MIV-negatief, smeer-positiewe pulmonêre TB 
pasïente en 18 gesonde veltoets positiewe vrywilliges van dieselfde woongebied. 
Immunofenotipering is gedoen deur middel van vloeisitometrie en is gekombineer 
met roetine hematologie vir die identifisering van periferie bloed immuunseltipes. 
Heel- bloed is ook in vitro gestimuleer met ‘n monoklonale anti-liggaam teen CD3 
en intrasellulêre IFN-γ en IL-4 bepaal deur vloeisitometrie. Limfosiet proliferasie is 
bepaal deur middel van getritïeerde timidien inkorporasie na blootstelling aan hitte 
geïnaktiveerde Mtb. Roetine mikrobiologiese toetse (speeksel smere en kulture), is 
vir die verloop van die 6 maande behandeling op elke pasïent gedoen. 
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Resultate 
In vergelyking met die van gesonde kontroles, was absolute perifêre bloed limfosiete 
en limfosietsubtipes beduidend onderdruk in pasïente by diagnose. Hierdie tellings 
het tydens behandeling genormaliseer, met die uitsondering van natuurlike doderselle 
en natuurlike doder T selle. ‘n Voorheen onbeskryfde subtipe van laasgenoemde 
selle het beduidend gekorrelleer met die uitkoms van behandeling. Na ‘n 4 uur 
stimulasie van die T-selreseptor, was IFN-γ produserende T-selle beduidend meer in 
pasïente by diagnose. Hierdie verskynsel het genormaliseer tydens behandeling. 
Bykomende kinetiese eksperimente het gewys dat IFN-γ produksie versnel is in 
pasïente by diagnose. Limfosiet proliferasie was laer in pasïente by diagnose en het 
genormaliseer tydens behandeling. Nie IFN-γ produksie of limfosiet proliferasie het 
gekorrelleer met die uitkoms van behandeling nie. Daar was ‘n konstante laë 
intrasellulêre IL-4 produksie in pasïente en kontroles, maar dit was nie beduidend 
laer in pasïente by diagnose in vergelyking met kontroles nie. In die pasïente wat 
stadiger gereageer het op behandeling, was intrasellulêre IL-4 produksie beduidend 
laer as in die  pasïente wat vinniger gereageer het. Hoë IL-4 uitdrukking is gevind in 
‘n klein hoeveelheid T selle in pasïente en kontroles. Bykomende eksperimente het 
getoon dat uitdrukking van aktiewe kaspase-3 in hierdie selle apoptose voorstel. 
Gevolgtrekking 
Limfosietsubtipe fenotipes, wat geassosieer word met tuberkulose, is meestal 
abnormaal slegs tydens aktiewe infeksie en slegs ‘n nuwe subtipe natuurlike doder T 
sel het ‘n korrellasie getoon met uitkoms van behandeling. Verhoogde intrasellulêre 
IFN-γ produksie en verlaagde limfosiet proliferasie is slegs waargeneem gedurende 
aktiewe infeksie en is nie geassosieer met uitkoms van behandeling nie. Die T helper 
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1/T helper 2 (Th1/Th2) hipotese kon nie bewys word in die konteks van tuberkulose 
nie, maar konstante IL-4 produksie mag ‘n moontlike rol as groeifaktor speel. 
 viii
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THE INVESTIGATION OF PERIPHERAL BLOOD 
CELLULAR IMMUNE RESPONSES DURING 
INFECTION WITH MYCOBACTERIUM TUBERCULOSIS 
 
Null hypothesis 
1. Patients with tuberculosis have normal peripheral blood immunophenotypes 
and cellular immune responses. 
2. Treatment response is not influenced by patients’ immune status at diagnosis. 
 
Alternative hypothesis 
1. Patients’ peripheral blood immunophenotypes and cell-mediated immune 
responses in peripheral blood of patients are altered during active 
tuberculosis. 
2. Treatment response is influenced by patients’ immune status at diagnosis. 
 
Aims 
1. To define lymphocyte subsets in patients’ blood by immune phenotyping at 
various time points during treatment and compare them with those of healthy 
control subjects. 
2. To define the cytokine production by patients’ and control subjects’ 
lymphocytes in response to stimulation in comparison with those of healthy 
control subjects. 
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3. To find correlations of immune parameters with routine microbiological data 
that define fast and slow responders to treatment.  
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1.  GENERAL INTRODUCTION 
 
1.1  TUBERCULOSIS AND THE IMMUNE RESPONSE 
 
TB has been a global health problem for millennia and it is estimated that a third of 
the world’s population is presently infected with Mycobacterium tuberculosis (Mtb), 
its causative organism, which was discovered by Robert Koch in 1882. Evidence for 
TB has been found in a 2400 year old mummy and was referred to in ancient Greek 
literature (http://www.state.nj.us/health/cd/tbhistry.htm). Drugs to treat TB were only 
discovered in 1944. The bacterium has defied enormous efforts to control it and still 
thrives, particularly in poorer communities, and the appearance of HIV and drug 
resistance is aggravating the problem. Deaths from TB are estimated to be 2-3 
million annually. 
For immunologists it has been of great interest that only an estimated 5-10% 
of Mtb-infected, HIV-uninfected individuals develop active disease, the remainder 
being protected from illness by their immune system. The Bacille Calmette-Guérin 
(BCG) vaccine primarily protects young children from disseminated forms of the 
disease but is not effective in protecting adults from pulmonary TB. The discovery of 
the mechanisms of the natural protective resistance would be of great benefit in the 
efforts to stop the spread of the disease and save the lives of those who become ill. 
 
1.2  THE CELLS OF THE IMMUNE SYSTEM 
 
The immune system has two arms, the innate and the adaptive immune response [1]. 
The innate immune system responds rapidly to foreign invaders, has no memory and 
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the responding cells are the natural killer (NK) cells, neutrophils and 
monocyte/macrophages in the blood and the infected tissues. Although the 
orchestrated response of the innate immune cells plays an important part by 
engulfing and destroying micro-organisms, the main protective immune response is 
that of the adaptive immune system which responds more slowly and has a memory 
that enables it to respond faster after a re-exposure to the same foreign invader of the 
body. The adaptive immune system, in turn, has two arms, the humoral and cell-
mediated immune response. The B lymphocytes mediate the humoral response by the 
production of antibodies that bind specifically to the invader, whereas in the cell-
mediated response the players are the T lymphocytes comprising subpopulations T 
helper (Th) cells, that express the specific cluster determinant (CD) CD4, T cytotoxic 
(Tc) cells that express CD8, γδ T cells that express a T cell receptor (TCR) consisting 
of γ and δ chains instead of the usual α and β chains and NK T cells that express NK 
cell markers such as CD56 as well as the T cell marker CD3. Dendritic cells and 
monocyte/macrophages of the innate immune system act as antigen-presenting cells 
in the cell-mediated adaptive immune response. 
 
1.3  THE CELL-MEDIATED IMMUNE RESPONSE 
 
The adaptive immune response to Mtb infection has been the subject of extensive 
research because of its memory response which could be harnessed for the 
development of more effective vaccines. Although TB patients have antibodies to 
mycobacterial antigens in their circulation, these do not play an important role in the 
elimination of bacilli but the cell-mediated response and interferon-γ (IFN-γ) 
production by activated T lymphocytes is crucial [2]. This cytokine also activates 
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resident macrophages that phagocytose the bacilli in the lungs of an infected subject. 
During disease progression the mycobacteria replicate in the macrophages, resulting 
in the formation of granulomas and the attraction of lymphocytes to the perimeter of 
the granulomas in a chronic cell-mediated response. 
In a normal immune response invading micro-organisms are taken up by 
dendritic cells or macrophages, which are antigen-presenting cells that break down 
the mycobacterial antigens into peptides in the endosomes. The peptides then 
associate with major histocompatibility complex (MHC) Class II molecules and are 
transported to the cell surface where they are presented to the CD4 T helper cells [1]. 
CD4 T cells bearing the appropriate TCR recognize the presented peptides and enter 
the effector phase characterized by clonal expansion and production of cytokines 
which potentiate effector cells to eliminate the bacilli. This cytokine production 
defines the type 1 (Th1) and type 2 (Th2) helper cell responses, where IFN-γ and 
interleukin-2 (IL-2) characterize the cell-mediated Th1 response and IL-4 and IL-5 
the humoral Th2 response [3]. Many studies with mice have shown that the CD4 T 
cell subset is essential for the control of the infection (reviewed in [2]) and a cruel 
experiment of nature with humans has shown the same by the rising incidence of TB 
in patients infected with the HIV virus that kills its cellular host, the CD4 T cell 
subset (http://www.who.int/hiv/topics/tb/en/). 
The main role of IFN-γ is believed to be macrophage activation [2]. It is 
produced by CD4 and CD8 T cells and NK cells and, although insufficient alone, is 
an essential cytokine in the control of Mtb infection as shown by studies with gene 
knock-out mice (reviewed in [2]) and human subjects with defects in the IFN-γ or 
IFN-γ receptor genes are susceptible to serious infections with normally non-
pathogenic mycobacteria [4].  
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CD8 T cells classically recognize peptide antigens derived from endogenous 
cytosolic antigens that are degraded by the proteasome and are transported to the cell 
surface in association with MHC Class I molecules. Although Mtb antigens located 
in the phagosome do not appear to have access to the MHC class I processing 
pathway, there is recent evidence that this is possible and that there is a role for CD8 
T cells in the defense against Mtb (reviewed in [2]). Activated CD8 cells also 
produce cytokines and have been subdivided into Tc1 and Tc2 cells according to 
their cytokine profiles of IL-2/IFN-γ and IL-4/IL-5 respectively, and they are also 
capable of cytolysis of the infected cells mediated by the cytotoxic granule proteins 
perforin and granulysin [2].  
A third antigen-presenting pathway involving the CD1 molecules has more 
recently been identified (reviewed in [5]), in which lipid antigens are presented. Both 
intracellular and exogenous lipid antigens, which include mycobacterial antigens, can 
be accessed by CD1 molecules and presented to CD1-restricted CD8 T cells and 
NKT cells and the effector functions are IFN-γ production and cytotoxic activity. 
Following the effector phase of expansion of the antigen-specific T cells and 
clearance of the infection is the deletion phase during which the majority of the 
expanded effector cells are removed by programmed cell death or apoptosis while a 
small number survive and persist as memory cells, capable of rapidly re-starting the 
response in the event of a repeated exposure to the antigen [1]. Apoptosis is 
accompanied by distinct morphological changes, decrease in cell volume and 
fragmentation into apoptotic bodies which are rapidly phagocytosed by 
macrophages, preventing the release of mediators of a localized inflammatory 
response [6]. 
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Two types of apoptosis occur in activated T cells that are triggered by 
different signals [7]: (1) The engagement of death receptors such as Fas which, after 
their engagement of ligands, transmit intracellular signals by the recruitment of 
adaptor molecules such as Fas-associated death domain (FADD) which in turn 
recruit cysteine proteases, first pro-caspases which become activated and in turn 
activate effector caspases that destroy cell structure and integrity. This type of 
apoptosis is also termed activation-induced T cell death. (2) Cytokine withdrawal 
which results in poorly characterized intracellular signals and their transduction via a 
mitochondrial pathway that utilizes proteins of the Bcl-2 family and cytochrome c to 
activate the pro-caspases and effector caspases. This latter process is also termed 
activated T cell autonomous death and is the major mechanism of deletion of T cells 
responding to foreign antigen [7]. 
 
1.4  TREATMENT OF TUBERCULOSIS 
 
The standard therapy for TB is in accordance with the South African National 
Tuberculosis Program and is based on World Health Organization guidelines [8]. It is 
designated directly observed treatment short course (DOTS) and is described in 
detail in Chapter 2. For drug-susceptible TB cure a combination of 3 drugs has to be 
taken for 6 months and for drug-resistant TB the treatment is even more complex. 
There is therefore an ongoing search for better drugs to improve and shorten the 
treatment to prevent the spread of the disease during the early stages of treatment and 
recurrence in treated patients. To conduct drug trials it is necessary to monitor the 
infection and the only internationally accepted method of doing this is by staining the 
acid-fast bacteria in the sputum by means of the Ziehl-Nielsen (ZN) stain and 
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culturing the bacteria, for instance with the Bactec system. Additional surrogate 
markers for the infection are still needed and the measurement of immune system 
parameters of the patients in this study was planned with this in mind.  
 
1.5  FLOW CYTOMETRY AS AN INVESTIGATIVE TOOL IN THE  
       EVALUATION OF THE IMMUNE RESPONSE 
 
Flow cytometry is the detection of cells in suspension that have bound specific 
antibodies tagged with fluorochromes. The flow cytometer passes the labelled cell 
suspension through the beam of a laser that excites the relevant fluorescent dyes and 
the emitted light is measured by photomultipliers. The dedicated software calculates 
accurate and objective statistics. Two types of cell labelling are used:  
(1) Extracellular in which fluorochrome-labelled antibodies, usually monoclonal 
antibodies (mAb), are simply allowed to react with molecules expressed by the cells 
on the cell membrane. This method is used to identify and quantify lymphocyte 
subsets in immunophenotyping and is quick and very reproducible. (2) Intracellular 
labelling in which molecules inside the cells, such as cytokines, are detected with the 
specific antibodies. As living cells do not allow macromolecules like 
immunoglobulins to pass through the intact cell membrane, the cells have to be 
effectively killed to make the plasma membrane permeable to the antibodies. There 
are many different ways of achieving this permeabilization which is also dependent 
on the intracellular localization of the molecule of interest. This method is therefore 
subject to much greater variation in the results obtained [9]. When investigating 
molecules that are not constitutively expressed, such as cytokines, and have to be 
induced by a stimulus, additional variables come into play, namely the in vitro 
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culture conditions and the time after the stimulus at which the measurements are 
made which are like a “snapshot” taken of a short time span in the cells’ response. 
These variables have to be taken into consideration when interpreting the results. 
 
2.  STUDY SETTING, DESIGN AND SUBJECTS 
 
2.1  SETTING 
 
This study was done in the Ravensmead/Uitsig epidemiological field site in 
metropolitan Cape Town, where the incidence of new smear and/or culture-positive 
TB was on average 313/100 000 population/year from 1993-1998 [10]. More 
recently, the number of cases of TB reported in Cape Town in 2005 was 874/100 000 
population/year (http://www.capegateway.gov.za/Text/2006/5/tb_stats_2006.pdf). 
 
2.2  PATIENTS AND CONTROLS 
 
The study was approved by the Ethics Committee of the Faculty of Health Sciences 
at Stellenbosch University (reference number 99/039) and written, informed consent 
was obtained from all participants. Inclusion criteria included: age 18-65, sputum 
culture-positive for Mtb, HIV-negative, not pregnant; and for follow-up: no multi-
drug resistance, and taking at least 80% of prescribed dosages during the intensive 
phase of treatment. The presence of helminth infection or atopy in the patient group 
was not known. Twenty-one patients with first-time TB were enrolled and studied 
throughout treatment whereas 9 were only studied at diagnosis. Blood samples were 
taken at diagnosis prior to initiation of treatment and for follow-up at weeks 1, 5, 13, 
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and 26 after start of treatment (the last blood sample being taken on the last day of 
chemotherapy). Sputum smears and Bactec cultures were done on day 1 and 3, and 
week 1, 2, 4, 8, 13 and 26 after start of treatment. A total white cell count (WCC) and 
differential blood count was done on all blood samples using a Bayer Advia 120.  
The patients received standard therapy in accordance with the South African 
National Tuberculosis Program (based on WHO guidelines). Therapy consisted of a 
fixed drug combination (depending on body weight) containing isoniazid (320-
400mg/day), rifampicin (480-600mg/day), ethambutol (800-1200mg/day) and 
pyrazinamide (1000-1250mg/day) during the intensive phase (8 weeks) followed by 
rifampicin and isoniazid during the continuation phase (the remaining 18 weeks) 
under direct observation. Postero-anterior and lateral chest X-rays (CXR) were taken 
at commencement of treatment allowing a four week time window on either side of 
diagnosis. The chest radiographs were evaluated using a standardized method [11] by 
a physician who had no prior knowledge of the patient’s condition. The extent of 
disease was estimated using a one-dimensional view of the upright posterior-anterior 
radiograph and by using the right upper lobe as reference area.  
One blood sample was taken from each of 18 healthy HIV-negative, PPD skin 
test-positive (>15mm) volunteers resident in the same community to serve as 
controls. These participants had no clinical or radiological signs of active TB. 
 
2.3  PROCESSING OF SPUTUM SAMPLES FOR ZIEHL-NEELSEN SMEAR 
       AND CULTURE 
 
Sputum samples were processed for culture using standard methods [12], which 
included decontamination according to the Bactec 460TB System Procedure Manual 
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(Becton Dickinson, Maryland, USA) before inoculation into a Bactec 12B vial. The 
vials were incubated at 37 °C and the growth index (GI) was read daily. Sputum 
smears, direct and concentrated, were examined for acid-fast bacilli using the Ziehl-
Neelsen (ZN) stain and evaluated using the scoring system of the International Union 
against Tuberculosis and Lung Disease [13]. If multiple smears were done the smear 
with the highest grade was recorded for that time point. 
 
2.4  DEMOGRAPHIC DATA OF STUDY POPULATION 
 
The 21 patients that were followed up were all cured after 26 weeks of standard 
DOTS therapy. Three patients were infected with an Isoniazid-monoresistant strain 
of mycobacteria. After 8 weeks of treatment 15 patients were smear-negative and 6 
were smear-positive while only 8 were culture-negative and 13 culture-positive (two 
of these were Isoniazid-monoresistant). The week 8 Bactec culture was therefore 
used as the more sensitive indicator of early treatment response. No significant 
differences between fast and slow responders in CXR findings at diagnosis were 
found (including extent of disease and presence, number or size of cavities). The age 
and sex distribution of patients and their responder status is given in Table 2.1.  
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Table 2.1: Age and sex data of patients and controls
 Patients  Controls 
 Fast respondersa Slow responders  
Total (no.) 8 13 14 
Male (no.) 3 9 3 
Female (no.) 5 4 11 
Age (years) 18-51 19-50 20-56 
aas defined by negative sputum culture at week 8 
 
 
The time to positivity (TTP) is the number of days that the sputum cultures were 
incubated until they became positive for Mtb growth and is an indication of the 
bacterial load of the patient at time of diagnosis. The change in TTP’s after initiation 
of treatment is shown in Fig. 2.1. At week 13 only one patient was still culture-
positive. 
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Figure 2.1 
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Figure 2.1:  Time to positivity in days of sputum cultures of from diagnosis (Dx) 
to week (Wk) 13.  
Each dot represents data from one patient. The lines are at the median values for each 
time point. 
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3.  CHANGES IN LEUKOCYTE AND LYMPHOCYTE SUBSETS 
DURING TUBERCULOSIS TREATMENT; PROMINENCE 
OF CD3dimCD56+ NKT CELLS IN FAST TREATMENT 
RESPONDERS 
 
3.1  INTRODUCTION 
 
To clarify the mechanisms of protective immunity against Mycobacterium 
tuberculosis (Mtb) infection and disease in humans many reports have addressed the 
potential immunological defect(s) by comparing immune phenotypes in actively 
diseased patients to those with latent infection. Most of these investigations have 
focused on T lymphocyte subsets, particularly CD4+ and γδ T cells, generally 
reporting depressed CD4+ T cells in peripheral blood of TB patients [14-16] but 
results are discrepant for γδ T cells, where both elevated [17,18] and normal [19,20] 
numbers have been found. Only a few but inconclusive reports of B-lymphocyte and 
NK cell numbers in TB patients exist [14,16,21,22] and NKT cells have, to my 
knowledge, not been investigated in TB patients. Generally, contributors to TB 
susceptibility remain unclear and follow-up data during therapy are scanty.  
The aim of this study was to investigate immune parameters during therapy and 
this chapter describes a systematic follow-up of leukocyte counts and lymphocyte 
subsets in TB patients for the entire 26 week treatment period. Furthermore, due to 
the fact that the identification of high risk patients for slow response to chemotherapy 
would have important clinical implications, peripheral blood immunophenotypes 
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were analyzed as potential surrogate markers of early TB treatment response and a 
multivariate classification technique applied to identify fast and slow responders to 
treatment by immunophenotype at diagnosis. 
 
3.2  MATERIALS AND METHODS 
 
3.2.1  Reagents 
 
Fluorochrome-labelled mAbs anti-CD45-peridinin chlorophyll (PerCP), CD3-
phycoerythrin (PE), CD3-PerCP, CD4-fluorescein isothiocyanate (FITC), CD8-
FITC, CD19-FITC, CD56-FITC, γδTCR-FITC, IFN-γ-PE, IL-4-PE and rabbit anti-
active caspase-3-FITC were from BD-Bioscience. A rabbit FITC control antibody 
was not available from the manufacturer. OKT3 anti-CD3 antibody was spent 
hybridoma medium. The hybridomas were from ATCC. Vα24-PE was purchased 
from Beckman Coulter, saponin from Sigma and polyethylene glycol 4000 (PEG)  
from Merck. For the locations of the suppliers see Appendix (p.118).  
 
3.2.2  Immunophenotyping by flow cytometry 
 
Whole blood (50µl per test), anti-coagulated with sodium heparin, was washed once 
with phosphate-buffered saline (PBS). The cells were suspended in 100µl of 0.1% 
bovine serum albumin (BSA) in PBS and added to the required antibody mixtures. 
After 20 minutes at 4°C, cells were washed and red blood cells (RBCs) lysed at the 
same time by diluting with 3-4ml cold PBS containing 0.05% saponin and 3% PEG 
(lyse/wash buffer; saponin was chosen as lysing agent because it was noticed by a 
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colleague previously (J. Adams, personal communication) that RBCs in whole blood 
from TB patients frequently failed to lyse when treated with commercial lysing 
solution. The addition of 3% w/v PEG to the saponin buffer prevented damage and 
clumping of cells in blood obtained at diagnosis and also enhances the formation of 
antigen/antibody complexes [23]). After centrifugation at 700g the cell pellets were 
fixed in 4% formaldehyde in PBS and stored at 4°C in the dark until flow cytometric 
analysis in a Becton-Dickinson FACS Calibur® using CellQuest software®. 
Lymphocytes were gated in a CD45-PerCP (FL3) versus Side Scatter plot (10 000 
events in this gate were acquired) and these were further analyzed for expression of 
CD3 and CD4 (or CD8, CD19, CD56, γδTCR) in the FL1 and FL2 channels 
respectively. The lymphocyte sums calculated were all between 95 and 100%. 
Isotype control antibodies were not routinely used as the background cell surface 
staining of ex vivo blood lymphocytes is very low (not shown). 
 
3.2.3  Intracellular cytokine labelling 
 
This method is described in more detail in Chapter 4. Briefly, whole heparinized 
blood was mixed 1:1 with RPMI 1640 medium in polypropylene tubes and incubated 
at 37°C with or without 0.1µg/ml OKT3 antibody for 4 hours, with 10µg/ml 
Brefeldin A (BFA) present during the last 3 hours. After incubation the blood was 
diluted with cold lyse/wash buffer, centrifuged in the cold at 700g, and the cells in 
the pellet were labelled with mAbs in the above buffer containing 0.1% BSA for 20 
minutes in the cold. After one wash with cold lyse/wash buffer, the cell pellets were 
fixed in 4% formaldehyde in PBS and analyzed in the flow cytometer. 
 
 17
3.2.4  Classification of patients into treatment response groups 
 
In order to find possible differences between fast and slow responders to treatment, 
patients were divided into two responder groups according to Bactec culture status at 
week 8 after start of treatment. Of the 21 enrolled patients 8 were culture-negative 
(fast responders) and 13 culture-positive (slow responders) (Table 2.1). 
 
3.2.5  Statistical analysis 
 
Data for patients at diagnosis and at the end of treatment were analyzed for 
significant differences from those for healthy subjects by means of the Mann-
Whitney test. The Friedman test with Dunn’s post test was used to analyze 
longitudinal changes in parameters with respect to the diagnosis time point values.  
(* or #: p=0.01-0.05, ** or ##: p=0.001-0.01, *** or ###: p<0.001; asterisks refer to 
the Mann-Whitney test and hashes to the Friedman test). The Pearson Chi-square test 
and Fisher’s exact test were used to analyze categorical CXR data. 
To find the best combination of variables at diagnosis that may have potential for 
the prediction of early treatment response, as defined by the week 8 Bactec sputum 
culture, a Support Vector Machines analysis was performed, a multivariate 
discriminant classification technique that has received much attention in the 
statistical literature in the past few years [24]. Combinations of up to a maximum of 
5 variables were analyzed and, using the variables included in the optimal 
classification model, a leave-one-out cross validation table was constructed. 
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3.3  RESULTS 
 
3.3.1  Longitudinal changes in total and differential white cell count  
 
The total white cell count (WCC) and absolute neutrophil counts were significantly 
elevated in patients at diagnosis relative to controls (Fig. 3.1A, B) but returned to 
normal levels by the end of treatment. The absolute monocyte counts were also 
significantly elevated at diagnosis but then dropped dramatically to significantly 
depressed levels at week 26 (Fig. 3.1C). The absolute lymphocyte count of patients 
at diagnosis was significantly depressed at diagnosis but counts were no longer 
significantly different from controls at the end of treatment (Fig. 3.1D). 
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Figure 3.1:  Absolute leukocyte counts of healthy controls and TB patients. 
Counts were calculated from the total white cell count and differential blood count. 
A: Total WCC, B: neutrophils, C: monocytes, D: lymphocytes. The boxes extend 
from the 25th to the 75th percentile with a line at the median and the whiskers show 
the highest and lowest values. Data for patients at diagnosis (Dx) and at the end of 
treatment at week (Wk) 26 were analysed for significant differences from those for 
healthy subjects by means of the Mann-Whitney test (* p<0.05, ** p<0.01, 
*** p<0.001). The Friedman test with Dunn’s post test was used to analyze changes 
in parameters during the patients’ follow-up with respect to values at diagnosis 
(# p<0.05, ## p<0.01, ### p<0.001). 
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3.3.2  Lymphocyte subsets 
 
Percentages of T lymphocytes and NK cells were not significantly different from 
those of controls at diagnosis or at week 26 while percentages of B lymphocytes 
were depressed in patients at diagnosis (p<0.05) and recovered during treatment (not 
shown). The absolute lymphocyte subset counts were calculated from the subset 
percentages and absolute lymphocyte counts (Fig. 3.2). The absolute CD3+ T cell and 
absolute CD19+ B cell counts were significantly depressed in patients at diagnosis 
but at week 26 these were not significantly different from those of control subjects 
(Fig. 3.2A, B). Absolute CD56+/CD3─ NK cell counts at diagnosis showed a trend 
towards lower numbers (p=0.06) and remained depressed until week 26 (p<0.05, Fig. 
3.2C).  
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Figure 3.2:  Absolute lymphocyte subset counts of healthy controls and TB 
patients. 
Counts were calculated from the absolute lymphocyte counts and the percentages of 
subsets determined by flow cytometric immunophenotyping. A: T lymphocytes 
(CD3+), B: B lymphocytes (CD19+), C: NK cells (CD3-CD56+). Box and Whisker 
plots and statistical analyses as for Fig. 3.1 (Mann-Whitney test * p<0.05, ** p<0.01, 
*** p<0.001, Dunn’s post-test # p<0.05, ## p<0.01, ### p<0.001). 
 24
3.3.3  T lymphocyte subsets 
 
The percentages of CD4+, CD8+ and γδ T cells and the CD4:CD8 ratio at diagnosis 
and at week 26 were not significantly different from those of control individuals and 
only small fluctuations were detected during follow-up. Two populations of NKT 
cells were detected that differed in their levels of expression of CD3: a CD56+ cell 
population which expressed CD3 levels comparable to conventional T cells 
(CD3bright/CD56+ NKT cells) and one that expressed reduced levels (CD3dim/CD56+ 
NKT cells). The percentages of CD3bright/CD56+ NKT cells in patients at diagnosis 
and at week 26 were not significantly different from those of controls (not shown) 
and CD3dim/CD56+ NKT cells are described in detail below. Absolute numbers of T 
cell subsets, calculated from the absolute lymphocyte count and the percentages 
determined by immunophenotyping are illustrated in Fig. 3.3. CD4+ T cell numbers 
(Fig. 3.3A) were significantly depressed at diagnosis relative to control subjects 
(p<0.01) and, while numbers increased significantly during treatment, they were still 
lower at week 26 than in controls (p=0.06). CD8+ T cell counts (Fig. 3.3B) showed 
no significant differences or variation and γδ T cell counts were significantly 
depressed (Fig. 3.3C, p<0.05) at diagnosis but recovered during treatment to normal 
levels at week 26. Absolute numbers of CD3bright/CD56+ NKT cells were lower at 
diagnosis (p=0.06) and at the end of treatment (p<0.05, Fig. 3.3D). 
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Figure 3.3 
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Figure 3.3:  Absolute T cell subset counts of healthy controls and TB patients. 
The subset counts were calculated from the absolute T cell counts and the 
percentages of the subsets determined by flow cytometric immunophenotyping. A: 
CD4+ T cells, B: CD8+ T cells, C: γδTCR+ T cells, D: CD3bright/CD56+ NKT cells. 
Box and Whisker plots and statistical analyses as for Fig. 3.1 
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3.3.4  A CD3dim/CD56+ NKT cell subset was more prominent in patients 
 
An unusual subset of lymphocytes was detected more frequently in patients (9 of the 
21 patients had ≥2% at diagnosis) than in controls (2 of 14 had ≥2%). In the flow 
cytometric analyses, of which Fig. 3.4 is an example, these cells were weakly CD3+ 
(CD3dim), CD4–, weakly CD8+ or CD8–, and CD56+, shown in region R2 in Fig. 
3.4D, and also γδTCR– (not shown). The number of cells in region R2, as illustrated 
in Fig. 3.4, expressed as a percentage of the cells in the CD45 gate, was determined 
for all blood samples. Fig. 3.5A shows increased percentages of CD3dim/CD56+ NKT 
cells in patients at diagnosis relative to control subjects although this was not 
statistically significant (p=0.23). Very low or undetectable numbers remained so 
during follow-up while higher numbers persisted and sometimes increased after start 
of treatment (shown for fast and slow responders in Fig. 3.5C); the highest recorded 
was 20.3% at week 1.  
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Figure 3.4:  A representative lymphocyte subset analysis of flow cytometric data 
from a patient with a prominent CD3dim/CD56+ NKT cell population.  
A: Gating of the CD45bright low side scatter total lymphocyte population.  
B, C, D: The gated lymphocytes analyzed for CD3 and CD4, CD8 and CD56 
expression, respectively. Region R2 in Fig. 4D contains the CD3dim/CD56+ NKT 
cells. 
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Figure 3.5:  CD3dim/CD56+ NKT cell percentages in the lymphocyte gate.  
A: Controls and patients at diagnosis compared with the Mann-Whitney test.  
B: Patients at diagnosis grouped into slow responders to treatment (culture(+) at 
week 8) and fast responders (culture(-) at week 8), compared with the Mann-Whitney 
test. C: Mean percentages of CD3dim/CD56+ NKT cell counts with standard deviation 
error bars in the slow and fast responder patient groups from diagnosis to end of 
treatment.
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3.3.5  Differences between treatment response groups 
 
When percentages and absolute numbers of each cell type at diagnosis in fast 
responders were compared to those at diagnosis of slow responders with a Mann-
Whitney test, the percentage and absolute count of CD3dim/CD56+ NKT cells at 
diagnosis were the only single variables that correlated significantly with treatment 
response – they were significantly higher at diagnosis in fast responders (p=0.01, Fig. 
3.5B). The percentages of CD3dim/CD56+ NKT cells did not change significantly 
during follow-up and are shown for the fast and slow responding patients in Fig. 
3.5C. 
As the CD3dim/CD56+ NKT cell numbers at diagnosis did not correlate with 
treatment response in all patients, a multivariate classification technique was used to 
find combinations of variables that may more accurately classify patients into fast 
and slow responders. Differences between early response phenotypes were most 
prominent at diagnosis and the variables at diagnosis that were used for the analysis 
were the absolute numbers of leukocyte, lymphocyte and T cell subsets. The Support 
Vector Machines discriminant analysis showed that the best classification of patients 
into the two treatment response groups could be obtained with just two variables 
(Fig. 3.6): absolute CD3dim/CD56+ NKT cells and absolute NK cells which correctly 
classified all 13 slow responders and 5 of 8 fast responders in a leave-one-out cross 
validation. Absolute NK cell counts at diagnosis alone did not correlate with 
treatment response (not shown).  
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Figure 3.6 
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Figure 3.6:  Support Vector Machines analysis of phenotyping variables for the 
prediction of treatment response as defined by week 8 sputum culture. 
The graph shows the overall prediction accuracy versus the number of variables 
included in the analysis. The two variables that gave a prediction accuracy of 0.85 
were absolute CD3dim NKT cells and absolute NK cells. The analysis was performed 
by Dr Martin Kidd. 
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3.3.6  CD3dim/CD56+ NKT cells produce IFN-γ and IL-4 
 
To assess functional aspects of CD3dim/CD56+ NKT cells an analysis was done of 
flow cytometric data of intracellular IFN-γ and IL-4 measurements in saponin-
permeabilized T cells after a 4-hour stimulation of whole blood with anti-CD3 mAb, 
described in detail in Chapter 4. In samples from patients with a prominent 
CD3dim/CD56+ NKT cell population these cells were discernible in the CD3-PerCP 
versus side scatter plots used for gating the T lymphocytes. The CD3dim and CD3bright 
cells were analyzed separately in all diagnosis blood samples that had high numbers 
of CD3dim T cells. A CD56 mAb was not routinely used in the intracellular cytokine 
determinations but was included on two occasions and these analyses showed that 
approximately 90% of the CD3dim  T cells were CD56+. IFN-γ was only produced by 
some of the patients and the CD3dim and CD3bright cells produced comparable low 
levels of this cytokine (Fig. 3.7B,C). All patients showed IL-4 production by both 
stimulated and unstimulated T cells and this tended to be higher in CD3dim  T cells 
(Fig. 3.7D,E). The CD3dim population contains more cells that express active  
caspase-3, an indicator of apoptosis, and this expression correlates with higher levels 
of intracellular IL-4 (Fig. 3.7F,G). It is however not known if these cells are also 
CD56+. 
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Figure 3.7:  Intracellular cytokine analysis of permeabilized lymphocytes from 
whole blood. 
Blood from two patients at diagnosis was incubated for 4 hours with or without 
stimulation with 0.1µg/ml anti-CD3 and the lymphocytes were permeabilized with 
saponin and labelled with mAbs as described in Materials and Methods of Chapter 4. 
A: Gating of CD3dim (R1) and CD3bright (R2) T cells in a CD3-PerCP versus SSC plot 
of leukocytes from the first patient. B-E: Histograms of the gated cells showing IFN-
γ (B, C) and IL-4 (D, E) expression. Overlaid histograms are:  (▬) stimulated, 
specific antibody, (·····) unstimulated, specific antibody, (----) stimulated, control 
antibody. F-G: Dot plots of similarly gated unstimulated T cells from the second 
patient showing co-expression of caspase-3 and IL-4. The position of the quadrant 
markers was determined by a PE-labelled control antibody (not shown). 
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3.4  DISCUSSION 
 
The data in this chapter show significant changes in absolute numbers of neutrophils, 
monocytes and lymphocyte subsets during active TB. That these changes occur 
already during the first weeks of treatment is important as it strongly suggests that 
TB patients tested at different time points during their treatment should not be 
grouped together in the analysis of results. A CD3dim/CD56+ subset of NKT cells was 
found to be more prominent in TB patients and correlates with a faster treatment 
response. A multivariate classification technique identified CD3dim/CD56+ NKT 
cells, in combination with NK cells, at diagnosis as variables indicating the 
likelihood of culture conversion early during TB treatment. NKT cells have, to my 
knowledge, not been reported in the context of TB disease and the reported findings 
support the future inclusion of these cells in the search for surrogate markers for 
treatment response.  
The interesting subset of NKT cells that was detected expressed CD56 and 
reduced levels of CD3 and was either double negative (DN) or weakly CD8+. NKT 
cells, which express CD3 and to a variable degree the NK cell markers CD56, CD57 
and CD161 [25-27], are a heterogeneous population in mice and humans with several 
subsets that differ in phenotype, TCR repertoire, MHC restriction and cytokine 
profile, as reviewed in [27]. “Classical” NKT cells express an invariant TCR with 
Vα24 (Vα14Jα281 in the mouse, now Vα14-Jα18), are CD1d restricted and express 
the NK cell marker CD161 or NKR-P1A. Two subsets of non-classical NKT cells do 
not express this invariant TCR. Human CD56+ NKT cells are abundant in the liver, 
are predominantly CD8+ or DN and Vα24 TCR-negative, have cytotoxic capacity 
and produce Th1 and Th2 cytokines when stimulated in vitro [28].  
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As the detection of the CD3dim/CD56+ NKT cells was unexpected, a Vα24 
antibody was not routinely included in the panel but some additional phenotyping 
with this antibody indicated that these cells did not express the invariant TCR (not 
shown). The possibility of artefactual CD3dim staining of NK cells due to non-
specific binding to Fc receptors must be considered but this is unlikely as the 
antibodies to CD4, CD19 and γδTCR were of the same (IgG1) isotype and did not 
stain the cells. Furthermore, NK cells do not express the high affinity Fcγ receptors 
CD32 and CD64 and can be seen as a clearly CD3-negative population in Fig. 4D. 
The reduced expression of CD3 could be the result of TCR downregulation 
[29] and the CD3dim/CD56+ NKT cells could be an activated subset of 
CD3bright/CD56+ NKT cells, but only a weak inverse correlation between the 
percentages of these NKT cell subsets (Spearman correlation coefficient -0.34, not 
shown) was found. Takayama et al [30] demonstrated that a CD122+  subset of 
human CD8+ T cells with intermediate TCR expression in the peripheral blood that 
produce high levels of IFN-γ and are also potently cytotoxic.  
Peripheral blood CD56+ T cells are increased during the early phase of 
Plasmodium falciparum or Plasmodium vivax infections in humans [31], suggesting 
an important role in the immune response to intracellular pathogens. Slifka et al. [32] 
found that 90% of virus-specific CD8+ and CD4+ T cells from choriomeningitis 
virus-infected mice co-express one or more NK cells markers for more than 500 days 
post-infection. In the patients of our study not much variation was found in the 
percentages of CD3dim/CD56+ NKT cells over time and they could represent a similar 
persistent population specific for mycobacterial antigens. 
The observation of the often higher numbers and percentages of 
CD3dim/CD56+ NKT cells in patients indicates that this cell population is expanded in 
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the blood of some TB patients, and that these patients are able to clear the infection 
more efficiently after the initiation of chemotherapy. As CD3dim/CD56+ NKT cells 
appear to produce variable IFN-γ and IL-4, it can be postulated that they are cells 
that have been activated, as could be indicated by their reduced CD3 expression, and 
are at variable stages between activation and apoptosis. This is supported by the 
finding that they contain a higher percentage of cells expressing active caspase-3 and 
that they produce more intracellular IL-4. Previous findings have associated 
intracellular IL-4 expression in lymphocytes with mitochondrial apoptosis markers 
[33]. Therefore CD3dim/CD56+ NKT cells could be indicators of an active immune 
system in TB patients and would accelerate clearance of the infection by antibiotics. 
The other variable that, together with CD3dim/CD56+ NKT cells, had 
predictive value according to the multivariant discriminative analysis, was the 
absolute NK cell count. Interestingly, a higher NK cell count is partially indicative of 
a slow response to treatment. A higher NK cell count in the peripheral blood may be 
the result of an inability of these cells to migrate into infected tissues. In humans NK 
cells are present in tuberculous pleural effusions [34] and in mice infected with Mtb 
NK cell numbers in the lung increase over the first 21 days of infection although 
their removal does not affect host resistance. A role of NK cells in the control of TB 
has been suggested by the results of in vitro studies with human NK cells and Mtb-
infected monocytes [35-37]. 
Monocytes/macrophages are important components of the innate immune 
response to mycobacterial infections and the dramatic change in the absolute 
monocyte counts in the patients between diagnosis and week 26 should be noted. The 
surprising finding here is that their numbers are significantly depressed in fully 
 41
treated patients and it is unknown what causes this depressed absolute monocyte 
count. 
To determine whether the depressed absolute monocyte, NK cell and 
CD3bright/CD56+ NKT cell counts at the end of treatment could contribute to 
increased susceptibility to TB relapse [10], phenotyping needs to be performed on 
larger numbers of blood samples taken after cessation of antibiotic treatment with 
subsequent long-term clinical follow up.  
A drawback of this study is that the patient numbers in the two treatment 
response groups are small and therefore the accuracy of the statistical classifications 
is limited. It is also not optimal that, for logistical reasons, the week 26 blood 
samples were taken on the day of the last dose of antibiotics and not after cessation 
of drug therapy. It is unknown whether drug treatment directly affects cell counts. 
In summary, peripheral blood white cell counts change rapidly during 
treatment and some counts at diagnosis hold promise as surrogate markers of 
treatment response. Further prospective studies with larger numbers of patients are 
now needed to evaluate the role of immunophenotyping in general and of 
CD3dim/CD56+ NKT cells specifically, including their functional characterization. 
The role of these cells in predicting differential outcomes at month six and the 
development of recurrence after cure needs to be assessed. 
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4.  CHANGES IN THE KINETICS OF INTRACELLULAR IFN-γ 
PRODUCTION IN TB PATIENTS DURING TREATMENT 
 
4.1  Introduction 
 
Despite the ongoing global TB problem and extensive research into protective 
immunity against this intracellular pathogen, mechanisms of protective immunity 
against Mycobacterium tuberculosis (Mtb) in humans have yet to be fully clarified. 
Immunological parameters that contribute to TB susceptibility remain unclear and 
markers of treatment response phenotypes are still elusive. 
Numerous reports have addressed the potential immunological defect(s) in 
infected individuals that have developed active TB in comparison to those who have 
remained healthy in spite of infection. As IFN-γ is required for a Th1 immune 
response to Mtb infection, this cytokine has been measured ex vivo in serum [38], 
bronchoalveolar lavage fluids [39] and pleural effusions of TB patients [40] or in 
culture supernatants of lymphocytes isolated from these body fluids and stimulated in 
vitro with mycobacterial antigens. In the majority of the latter studies secreted IFN-γ 
was measured by ELISA, less frequently by ELISPOT, and in some cases 
intracellular IFN-γ was measured by flow cytometry (FC). The results of these 
studies have varied considerably. Of 33 such studies using mycobacterial antigen 
stimulation of isolated lymphocytes or whole blood, 13 found that patients produced 
less IFN-γ than controls, 13 found that they produced more, and 7 found no 
difference (summarized with assay variables in Tables 4.1-3). Another paradox is 
added by findings of high IFN-γ levels in serum [38], pleural fluids [40,41] and lungs 
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[39] of TB patients. There is therefore still a need for more work to clarify these 
discrepant results. 
 
 
Table 4.1: Reports that found IFN-γ production lower in patients compared to 
controls 
Reference Assay Stimulant Incubation Serum  Endotoxin
[42] ELISA Mtb 4 days human   ? 
[43] ELISA Mtb 10,30,38, 
65kDa Ag 
4 days human  50pg/ml 
[44] ELISA 30kDa Mtb Ag 48 hrs FCS ? 
[45] FC Mtb 48 hrs human  ? 
[46] ELISA H37Ra Mtb 4 days FCS <10pg/ml 
[47] FC 
ELISA 
PPD,Mtb Ag85 4 days FCS ? 
[48] ELISA Mtb 30,32kDa Ag 4 days FCS <1.5pg/ml 
[49] ELISA Mtb 4 days human  ? 
[50] ELISPOT Mtb 4 days human  ? 
[51] ELISA PPD 4 days FCS <0.1pg/ml 
[52] FC BCG 6 days autologous 
plasma 
? 
[38] ELISA Mtb 5 days human ? 
[53] ELISA CFP10 5 days whole blood ? 
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Table 4.2: Reports that found IFN-γ production higher in patients compared to 
controls 
Reference Assay Stimulant Incubation Serum  Endotoxin
[54] ELISA ESAT-6 
PPD 
5 days human  ? 
[55] ELISPOT ESAT-6  
H37Ra lysate 
48 hrs ? ? 
[56] ELISA Mtb sonicate 4 days human  ? 
[57] ELISPOT ESAT-6  12 hrs FCS ? 
[58] ELISA ESAT-6, 
PPD 
24 hrs whole blood ? 
[59] ELISA ESAT-6  5 days  autologous 
plasma 
? 
[60] FC 30kDa Mtb Ag 6 days FCS ? 
[61] ELISA TB27.4 Mtb Ag 4 days human  <1pg/ml 
[62] ELISPOT ESAT-6 1 and 6 
days 
autologous 
plasma 
? 
[63] ELISPOT PPD 24 hrs calf serum ? 
[64] FC ESAT-6 6 hrs whole blood ? 
[65] ELISPOT ESAT-6 
peptides 
40 hrs FCS ? 
[66] ELISA Mtb 9.8,39A,40 
Ag85B 
6 days human <5pg/ml 
 
 
Table 4.3: Reports that found no difference in IFN-γ production in patients and 
controls 
Reference Assay Stimulant Incubation Serum  Endotoxin 
[67] ELISPOT Mtb extract 4 days FCS ? 
[59] ELISA PPD, Mtb Ag85 5 days autologous 
plasma 
? 
 
[60] ELISA 30kDa Mtb Ag, 
Mtb extract 
6 days FCS ? 
[68] ELISA ESAT-6   
and peptides 
3 days human ? 
[69] ELISA 10, 30, 85A, 
85B Mtb Ag 
5 days autologous 
plasma 
negative 
[65] ELISPOT ESAT-6 40 hrs FCS ? 
[66] ELISA Mtb culture 
filtrate, cell wall 
6 days human ? 
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4.2  MATERIALS AND METHODS 
 
4.2.1  Patients and controls 
 
The same 21 patients described in Chapter 3 were followed up at the same time 
points and compared to the same controls. Bloods from an additional 6 HIV-negative 
patients at diagnosis and 4 HIV-negative, skin test-positive additional controls were 
used for the IFN-γ kinetics experiments 
 
4.2.2  Reagents 
 
Fluorochrome-labelled mAbs CD3-PerCP, CD8-FITC, and IFNγ-PE (clone 4S.B3) 
were from BD-Bioscience. Anti-CD3 mAb for stimulation was OKT3 in the form of 
hybridoma medium (hybridomas obtained from ATCC), diluted in tissue culture 
medium; the concentration of mouse immunoglobulin determined by ELISA. RPMI 
1640 medium was from Gibco-BRL, saponin and Brefeldin A from Sigma, 
polyethylene glycol 4000 from Merck and purified protein derivative (PPD) was 
from Weybridge Veterinary Institute (UK). A stock solution of 2mg/ml in PBS 
(endotoxin <0.125EU/ml) was diluted in RPMI 1640 for adding to cultures to a final 
concentration of 3µg/ml. Heat-killed Mtb for stimulation was prepared from H37Rv 
strain of Mtb cultured in 7H9 medium. The bacteria were washed twice in 0.01% 
Tween 80 in saline, resuspended in Tween/saline, heated in a heating block 
preheated to 101°C for 20 minutes and frozen at -80°C in aliquots. After thawing the 
stock was diluted in RPMI 1640 medium and added to cultures to give a final 
concentration of 5x105 cfu/ml. 
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4.2.3  Intracellular cytokine determination  
 
In a pilot study and subsequent optimization experiments for this study clumping of 
cells was consistently observed in whole blood from patients at diagnosis after 
stimulation with live Mtb or PPD in overnight culture. The light scatter properties of 
the leukocytes in these cultures were abnormal, the cell number being reduced and 
cell debris increased compared to those of control individuals and patients that had 
received treatment (not shown). These observations suggested that there may be 
rapid cell death in blood cultures from patients at diagnosis when stimulated with 
mycobacterial antigen and possible loss of the very cells that were to be analyzed by 
flow cytometry. Soluble anti-CD3 mAb was therefore used as stimulus and 
intracellular IFN-γ production could be detected in T cells after a four-hour 
stimulation with no change in light scatter or clumping of cells obtained from 
patients at diagnosis. 
Blood was collected in sodium heparin tubes and processed within 3 hours of 
venesection. For the stimulation, 750µl of whole blood was mixed with 750µl RPMI 
1640 with bicarbonate, 25mM HEPES, penicillin/streptomycin and 50µM 2-
mercaptoethanol (RPMI+) in 12ml round-bottom polypropylene tubes. After 30mins 
in a 37°C water bath, OKT3 mAb was added to a final concentration of 0.1µg/ml. 
Incubation was continued for another 4 hours, with 10µg/mL Brefeldin A (BFA) 
present during the last 3 hours to stop secretion of cytokines. 
As commercial RBC lysing solution was previously found to be ineffective 
with blood from TB patients at diagnosis and the commercial intracellular cytokine 
labelling kit protocol was too long for the restricted working conditions in the 
category 3 containment TB laboratory, a rapid method without fixation of cells was 
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used, based on a method described by Holmes et al [70] for the labelling of 
intracellular antigens. It was modified for use with whole blood and simultaneous 
cell surface staining by reducing the saponin concentration from 0.3% to 0.05% and 
by the addition of 3% w/v PEG 4000 to the saponin buffer to prevent clumping and 
loss of leukocytes in TB patients’ diagnosis blood samples. As this concentration of 
PEG has also been shown to enhance the formation of antigen/antibody complexes 
[23], it did not interfere with the labelling of cellular antigens with monoclonal 
antibodies. 
After incubation/stimulation the blood was diluted to 20ml with cold PBS 
containing 0.05% saponin, and 3% PEG (lyse/wash buffer) and centrifuged in the 
cold at 700g after RBC lysis was complete. The cell pellet was resuspended in 500µl 
of 0.1% bovine serum albumin (BSA) in lyse/wash buffer, 100µl aliquots of the 
suspension were added to premixed antibodies (CD3-PerCP, CD8-FITC and IFNγ-
PE (or control mAb)) and left for 20 minutes in ice water. After one wash with 
lyse/wash buffer at 4oC, the cell pellets were suspended in cold, freshly diluted 4% 
formaldehyde in PBS and stored at 4°C in the dark until flow cytometric analysis the 
following day on a Becton-Dickinson (BD) FACS Calibur® with CellQuest 
software®.  
T lymphocytes were gated in a CD3-PerCP versus SSC plot (50 000 events in 
this gate were acquired) and CD8-positive and –negative cells were then gated in a 
CD3-PerCP versus CD8-FITC plot of the T cells. In separate plots of IFNγ-PE 
versus CD8-FITC the percentage of cytokine-positive cells in the CD8-positive and 
CD8-negative population (assumed to be CD4+ and henceforth referred to as CD4 T 
cells) were obtained from the quadrant statistics. Because the staining of the negative 
cells with the isotype control antibody was slightly different to that of the specific 
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antibody (see Fig. 4.1), the quadrant marker was first placed in the plot for the 
unstimulated cells and the same position was used for the plot of the stimulated cells.  
 
4.2.4  Lymphocyte proliferation 
 
A whole blood lymphocyte proliferation test with mycobacterial antigens as stimulus 
was performed in parallel with intracellular IFN-γ. These assays were done as part of 
the same study by Ilse Crous and Shweta Brahmbhatt, two colleagues in the 
Department of Biomedical Sciences at the University of Stellenbosch Faculty of 
Health Sciences, and the results are included here for the sake of completeness. 
Whole blood was diluted 1 in 10 with RPMI+. Aliquots of 180µl were dispensed into 
wells of 96-well round-bottom tissue culture plates with 20µl of the stimulants PPD 
(3µg/ml final concentration) or heat-killed Mtb (5x105cfu/ml final concentration) and 
incubated for 6 days at 37°C in 5% carbon dioxide. Tritiated (3H) thymidine was then 
added at 0.5µCi/well and the plates incubated for another 6 hours before harvesting 
with a custom-built harvester onto glass fibre discs which were counted in a 
scintillation counter. The medians of quadruplicate counts per minute (cpm) of 
unstimulated cultures were subtracted from the medians of stimulated cultures. 
 
4.2.5  Statistical analysis 
 
Data for patients at diagnosis and at the end of treatment were analyzed for 
significant differences from those for healthy subjects by means of the Mann-
Whitney test. The patients were divided into two groups according to whether they 
were sputum culture-positive (slow responders) or -negative (fast responders) after 8 
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weeks of treatment and data for patients in these two groups were also compared by 
means of the Mann-Whitney test. The Spearman correlation coefficient was 
determined to test for correlation between two data sets (*: p=0.01-0.05, 
**: p=0.001-0.01, ***: p<0.001). 
 
4.3  RESULTS 
 
4.3.1  Intracellular IFN-γ 
 
The unstimulated blood samples mostly contained insignificant numbers of IFNγ-
positive T cells at or near background staining which varied around approximately 
50 events or 0.2%. These insignificant percentages were not subtracted from those in 
the stimulated cultures. Irrelevant mouse monoclonal antibody (hybridoma 
supernatant) did not stimulate IFN-γ production and was not routinely added to 
unstimulated control cultures. Fig. 4.1 is a representative flow cytometric analysis 
plot of the lymphocytes in the blood from a patient at diagnosis, labelled with mAbs 
to IFN-γ, CD3 and CD8. 
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Figure 4.1 
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Figure 4.1:  Representative flow cytometric data of intracellular IFN-γ staining 
of leukocytes from whole blood. 
T lymphocytes gated in a CD3-PerCP versus SSC plots (region R1) and the CD8-
FITC and IFN-γ-PE staining of the gated cells is shown. To obtain the percentages of 
IFN-γ+ cells in the CD8 and CD4 subpopulations, the cells were gated further as 
described in Materials and Methods (not shown). The quadrant markers of the 
unstimulated cells were used as a reference for demarcating IFN-γ-negative and  
-positive cells in the stimulated samples. 
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Patients’ blood samples at diagnosis contained very variable percentages (up 
to 13%) of CD8  IFN-γ-producing T cells (Fig. 4.2A), which were significantly 
higher than in control subjects (p<0.001). In the week 1 blood samples the 
percentages of IFN-γ-producing cells were already reduced and decreased to normal 
levels at week 26 when treatment was completed. 
Numbers of IFN-γ+ CD4 T cells were lower (Fig. 4.2B) but there was still a 
significant difference (p<0.01) between the percentages in patients’ blood at 
diagnosis and control subjects and the numbers in patients decreased from week 1 
onwards similar to those in the CD8 population and at week 26 there was no 
significant difference between the percentages in patients and controls. There was a 
significant correlation between the percentages of IFN-γ+ cells in the CD4 and CD8 
T cell populations at diagnosis (Spearman correlation coefficient 0.6149, p<0.01, not 
shown). The decrease in the percentage of IFN-γ+ CD4 and CD8 T cells over time 
mirrored that of the decrease in bacterial load in the patients as indicated by the 
increase in time to positivity (TTP) of their sputum cultures (Fig. 2.1). 
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Figure 4.2:  Intracellular IFN-γ expression in T cells of TB patients and healthy 
skin test-positive control subjects after 4 hours stimulation of whole blood with 
anti-CD3 mAb.  
IFN-γ+ CD8 T cells (A) and IFN-γ+  CD4  T cells (B), expressed as % of gated CD8 
and CD4 cells respectively. The gating is described in Materials and Methods. Time 
points for patients are in weeks from diagnosis until treatment end at week 26. 
Horizontal lines represent median values for each set of data. Percentages in control 
subjects and patients at diagnosis were compared by means of a Mann-Whitney test 
(*: p=0.01-0.05, **: p=0.001-0.01, ***: p<0.001) 
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4.3.2  Kinetics of IFN-γ production 
 
The above findings of non-antigen-specific increased IFN-γ production during active 
TB are in agreement with those of others who have reported increased  
IFN-γ production in response to stimulation with various mycobacterial antigens by 
means of ELISA, ELISPOT or flow cytometry (FC), as shown in Table 4.2. 
However, a large number of studies have found the opposite or no difference (Table 
4.1 and 4.3 respectively).  
One of the reasons for this discrepancy could be the kinetics of the IFN-γ 
production. For logistical reasons, and to avoid in vitro artefacts, a short incubation 
of 4 hours with stimulant was chosen, whereas most other protocols used overnight 
or longer incubations. If the kinetics of IFN-γ production in patients at diagnosis 
were faster than in control subjects, measurement and comparison of IFN-γ 
production at different time points would lead to markedly different results. 
Increasing production in one group may coincide with declining levels in another 
group. To substantiate this hypothesis, blood of patients and controls was stimulated 
for 4 hours and 8 hours with anti-CD3 antibody and intracellular IFN-γ production 
was determined at both time points. BFA was added to both cultures for the last 3 
hours of incubation. Patients’ bloods taken at week 26 after completion of treatment 
were tested as well, although the patients tested at diagnosis and at week 26 were not 
the same individuals. 
The results (Fig. 4.3A) show a substantial drop in IFN-γ+ CD8 T cells from 4 
hours to 8 hours in 5 of the 7 patients tested at diagnosis. In the blood samples taken 
at week 26 and in healthy controls no clear kinetic pattern was observed. IFN-γ 
production in healthy controls could not be determined after overnight or longer 
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stimulation due to severe down regulation of CD3, which would prevent gating of T 
cells. The kinetics of IFN-γ production by CD4 T cells (Fig. 4.3B) was variable, with 
percentages of IFN-γ+ cells higher after 8 hours than after 4 hours in half the patients 
tested at diagnosis. Fig. 4.3 shows that there is variation in the kinetics of IFN-γ 
production not only between groups of patients and controls but also between 
individuals in each group and the results obtained would therefore depend on the 
chosen stimulation time. 
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Figure 4.3 
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Figure 4.3:  Kinetics of IFN-γ production by CD8 and CD4 T cells in TB 
patients and controls during the first 8 hours of stimulation. 
Whole blood was stimulated for 4 hours or 8 hours with anti-CD3 mAb, of which the 
last 3 hours was in the presence of BFA, and intracellular IFN-γ was labelled as in 
Materials and Methods. Kinetics in patients at diagnosis are compared with those in 
patients at the end of treatment (not the same individuals) and with healthy skin test-
positive controls in CD8 T cells (A) and CD4 T cells (B). 
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4.3.3  Lymphocyte proliferation 
 
These tests were performed by Ilse Crous and Shewta Brahmbhatt as part of this 
study and I gratefully include them here as the results help to explain the other 
findings.  
3H-thymidine uptake of lymphocytes stimulated in whole blood with heat-
killed Mtb was significantly depressed in patients at diagnosis relative to controls 
(Fig. 4.4A, p<0.05). Patients’ counts then increased rapidly to above normal during 
weeks 5-13 of treatment, when they generally became sputum culture-negative, and 
again fell to normal levels at the end of treatment. As this assay was a whole blood 
assay and it was also found that patients’ lymphocyte counts were depressed at 
diagnosis relative to control subjects (Chapter 3) the 3H-thymidine uptake of 20µl 
blood was normalized to 2x104 T cells, calculated from the total white cell count, 
differential count and CD3 immunophenotyping. The normalized counts followed a 
similar pattern during the follow-up period (not shown) but the difference in counts 
between control subjects and patients at diagnosis was no longer significant 
(p=0.083). Overall, while lymphocyte proliferation increased during treatment the 
percentages of IFN-γ-producing T cells decreased (as shown in Fig. 3.2), together 
with the reduction of bacterial load as indicated by a longer TTP (Fig. 2.1). In 
individual patients there was no significant inverse correlation between lymphocyte 
proliferation and intracellular IFN-γ but the TTP at week 4 correlated significantly 
with lymphocyte proliferation at the week 5 time point (Fig. 4.4B). This correlation 
was significant when 3H-thymidine uptake was expressed as median cpm per 20µl of 
blood (Spearman r=0.4455, p< 0.05) or as cpm normalized to 2x104 T cells 
(r=0.4576, p< 0.05). When PPD was used as stimulant in the cultures, there was no 
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difference in 3H-thymidine uptake between patients at diagnosis and control subjects 
and very little change in the counts during the follow-up period (not shown). 
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Figure 4.4 
 
0 5 10 15 20 25
0
10000
20000
30000
40000
50000 r=0.4455*
TTP at Wk4
M
ed
ia
n 
cp
m
 a
t W
k5
Controls Dx Wk 1 Wk 5 Wk 13 Wk 26
0
10000
20000
30000
40000
50000
Patients
*
M
ed
ia
n 
cp
m
A
B
 
 
 62
Figure 4.4:  3H-thymidine uptake after 7 days incubation of whole blood with 
heat-killed Mtb in TB patients and healthy skin test-positive controls.  
A: Median cpm for controls and patients at diagnosis and time points (weeks from 
diagnosis) during treatment. Horizontal lines represent median values for each set of 
data. Counts in control subjects and patients at diagnosis were compared by means of 
a Mann-Whitney test (*: p=0.01-0.05, **: p=0.001-0.01, ***: p<0.001). 
B: Correlation of time to positivity (TTP) of patients’ sputum cultures at week 4 with 
lymphocyte proliferation at week 5. TTP in days is plotted against median cpm and 
the Spearman correlation coefficient (r) is calculated. 
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4.3.4  Correlation with treatment response 
 
In order to find possible correlations of intracellular IFN-γ production or lymphocyte 
proliferation with treatment response, the patients were divided into two groups 
according to whether they were sputum culture-positive (slow responders) or  
-negative (fast responders) after 8 weeks of treatment, as in Chapter 3. There was no 
difference between CD8 or CD4 IFN-γ production or 3H-thymidine uptake at 
diagnosis in the two groups of patients.  
 
4.4  DISCUSSION 
 
Previously reported findings of IFN-γ production in vitro by stimulated lymphocytes 
of patients with TB have been contradictory and are summarized in Tables 4.1-3. 
Stimulation of lymphocytes in culture is subject to a large number of variables in the 
methodology. For example, the use of foetal calf serum (FCS), human AB serum or 
autologous plasma could have an effect, or the type of culture plates. Only 7 of the 
33 cited studies specify the endotoxin levels in the stimulants used. Endotoxin 
contamination in pg/ml concentrations could stimulate the monocytes in whole blood 
and in isolated PBMC’s and this could have secondary effects on the lymphocytes. 
The time in culture is another variable, which is examined in the present study. 
The data reported here, which show that stimulated lymphocytes from TB 
patients at diagnosis make significantly more intracellular IFN-γ than those from 
healthy controls after 4 hours of stimulation, agree with the cited studies in Table 4.2 
which used mycobacterial antigens as stimulus. Similar to our work, another study 
reported the use of soluble anti-CD3 mAb [71] and found similar results. These 
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authors assayed IFN-γ in the medium of 4-day lymphocyte cultures and showed 
increased levels in cultures from TB patients relative to healthy controls although 
they did not give comparative statistics. The focus of their study was the comparison 
of TB with pulmonary disease caused by non-tuberculous mycobacteria. 
Some explanation of the discrepant results of previous studies may be 
provided by the kinetic studies included in this thesis which have shown that 
patients’ CD8 lymphocytes at diagnosis are able to produce IFN-γ rapidly but that 
this production is short-lived and wanes after 8 hours. One could therefore postulate 
that, if IFN-γ levels were measured in culture supernatants after several days, the 
overall production would be low whereas in cultures from healthy subjects with a 
later onset of production, sustained for longer, it would be higher. It was shown here 
that IFN-γ kinetics show large inter-individual variation within each subject group 
and that the kinetics and the measured IFN-γ production change during treatment.  
The lack of correlation between lymphocyte proliferation and intracellular 
IFN-γ that was found here supports previous findings [67]. The overall depressed 
lymphocyte proliferation of patients’ lymphocytes at diagnosis in response to Mtb 
stimulation that was found by my colleagues in this study is associated with 
increased IFN-γ production measured after 4 hours of stimulation. These results can 
be explained if one postulates that the kinetics of the response to mycobacterial 
antigens is also accelerated, like that to non-specific TCR stimulation with anti-CD3 
mAb. In that case some stimulated lymphocytes would already have gone into 
apoptosis by day 7, when the cell cultures are pulsed with 3H-thymidine, and 
incorporation of the label would be reduced. This view is supported by my 
observations during optimization experiments of cell clumping in patients’ blood at 
diagnosis in the presence of mycobacterial antigens in overnight culture. The finding 
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of increased 3H-thymidine uptake with increased TTP, i.e. lower bacterial load, at 
week 4 could also indicate that there is reduced cell death in vitro with the clearance 
of the infection.  
Increased apoptosis of T cells in TB patients has been reported previously 
[45,46]. Hirsch et al  [46] found an inverse correlation between increased apoptosis 
of CD4+ and CD4─ T cells induced by Mtb in patients at diagnosis and IFN-γ in 
culture supernatants after 96 hours of culture, but there was no significant difference 
between treated patients and controls. Another study found a loss of IFN-γ positive 
CD4+ and CD4─ T cells in 40 hour Mtb-stimulated PBMC cultures from of TB 
patients relative to controls and a concomitant decrease of IFN-γ in culture 
supernatant as well as increased apoptosis [45]. These studies and ours suggests that 
pre-activated T cells are present in the peripheral blood of patients with active TB 
which is also supported by the finding of increased numbers of CD4 T cells 
expressing the activation marker CD38 in the peripheral blood of patients with active 
TB relative to cured patients and healthy, skin test-positive controls [15]. The 
presence of significant numbers of IFN-γ+ T cells in some of the skin test-positive 
control subjects in this study may be an indication that they have been recently 
infected with Mtb but have remained asymptomatic. However, because anti-CD3 is a 
non-specific stimulus, it could also mean that the T cells have been activated by 
another infectious agent. 
In summary, the data in this chapter have shown that T lymphocytes of 
patients with active TB proliferate below normal levels in response to stimulation 
with mycobacterial antigens and have the capacity for rapid production of IFN-γ 
after TCR stimulation. However, the kinetics of the response tends to be accelerated 
relative to controls and cured patients, but not sustained. As there was wide inter-
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individual variation in the kinetics of cytokine production in each group, it is difficult 
to recommend a single optimal time point for analysis of IFN-γ production. The 
detailed follow-up results also show that the measured parameters are affected by the 
bacterial load of the patients and change rapidly within the first weeks of treatment. 
The implications of the increased rapid intracellular IFN-γ responses during active 
mycobacterial infection need to be investigated as it is presently unclear whether this 
is a beneficial reaction or whether it indicates a brief and non-sustained and therefore 
inadequate effector mechanism. 
 
5.  INTRACELLULAR INTERLEUKIN-4 IN LYMPHOCYTES 
FROM PATIENTS WITH TUBERCULOSIS – EVIDENCE 
NECESSITATING A REVIEW OF ITS ROLE IN THE 
IMMUNE RESPONSE 
 
5.1  INTRODUCTION 
 
The Th1/Th2 Hypothesis postulates two different types of lymphocyte responses to 
stimulation with environmental or bacterial antigens that are defined by the cytokine 
production of the stimulated cells [3]. The Th1 response, characterized by, amongst 
other cytokines, IFN-γ production, is required in microbial infections while the Th2 
response, characterized by IL-4, IL-5, IL-10, IL-13 and others, is associated with 
humoral responses to helminth infections and allergens. The two responses are 
thought to have a reciprocally inhibitory effect on each other and an imbalance could 
cause inappropriate immune responses. In the context of TB in humans it has been 
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postulated that excessive IL-4 production may inhibit the required Th1 response to 
the microbial infection, which has been shown experimentally in mice infected with 
Leishmania parasites [72]. 
IL-4 is a pleiotropic growth factor produced by T cells, mast cells and 
activated basophils but protein and/or mRNA has also been reported to be produced 
by neutrophils [73], alveolar macrophages [74], dendritic cells [75], and human 
lymphoid and myeloid cell lines [76].  IL-4 receptors have been detected  on many 
cell types, including T and B lymphocytes, monocytes, granulocytes, fibroblasts, 
epithelial and endothelial cells [77] and IL-4 could be an autocrine/paracrine growth 
factor for these cells. Raised levels of IL-4 have been detected in cultures of T and B 
cells from patients with chronic lymphocytic leukaemia (CLL) thus maintaining the 
leukaemic cells’ extended viability in culture and in vivo (reviewed by Kay [78]). 
Levels of secreted IL-4 in cultures of stimulated T cells are low and 
notoriously difficult to measure in supernatants of stimulated PBMC’s. Some studies 
have attempted to do so in the context of TB but have not been able to detect it in 
significant concentrations [42-44,47], whereas others have found no difference in 
patients and controls [68], or higher levels in patients [56,67]. Intracellular IL-4 
measured by flow cytometry was found to be no different in patients and controls 
[64], lower in patients [47], higher in patients’ CD8 T cells [52] or CD4 T cells [45]. 
The Th1/Th2 hypothesis has thus not been confirmed in the context of human 
pulmonary TB and this study attempted to find additional evidence for its validity. 
As the findings could not be explained with the Th1/Th2 hypothesis, some 
supplementary in vitro experimental work was conducted to find an alternative 
explanation for the results. 
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5.2  MATERIALS AND METHODS 
 
5.2.1  Patients and controls 
 
The 21 patients for the follow-up study and 14 healthy controls for comparison were 
described in Chapter 3. Blood from three additional patients at diagnosis and two 
additional healthy control subjects was used for the supplementary experiments. 
  
5.2.2  Reagents 
 
Fluorochrome-labelled mAbs anti-CD3-PerCP, CD8-FITC, IL-4-PE (clone 8D4-8), 
HLA-DR-FITC, HLA-DR-allophycocyanin (APC) and rabbit anti-active caspase-3-
FITC were from BD-Biosciences. A rabbit control-FITC Ab is not supplied by the 
manufacturer. Anti-CD3 mAb for stimulation was OKT3 as in Chapter 4. RPMI 
1640 medium was from Gibco-BRL, saponin, BFA, lipopolysaccharide (LPS) and 
protease inhibitor cocktail from Sigma. The high sensitivity IL-4 ELISA kit was 
from R&D Systems and the Jurkat E6.1 T cell line was from ATCC. Recombinant 
IL-4 was a gift from Prof Bernard Ryffel of the University of Cape Town. 
 
5.2.3  Intracellular cytokine determination:  
 
The stimulation of whole blood with anti-CD3 antibody and the intracellular 
cytokine labelling has been described in Chapter 4. 
For the supplementary experiments with Jurkat cells and T cells, neutrophils 
and monocytes in whole blood incubated overnight with BFA, the labelling method 
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was modified to include a fixation step before the saponin treatment for the 
preservation of the light scatter of the cells: Jurkat cells or cultured whole blood was 
washed once with PBS and suspended in 0.1% BSA in PBS. An equal volume of 1% 
formaldehyde in PBS was added and after 15 minutes at room temperature the cell 
suspension was diluted with cold 0.1% BSA in lyse/wash buffer (see Appendix). 
When RBC lysis was complete, the samples were centrifuged, the supernatant 
aspirated and the pellet resuspended in the residual buffer. The cells were then 
labelled with mAbs as in Chapter 4. In the analyses of the flow cytometric data T 
lymphocytes were gated in a CD3-PerCP versus SSC plot (50 000 events in this gate 
were acquired). The IL-4 expression was bimodal and strongly IL-4-positive cells 
(IL-4high) were determined in the conventional way, using quadrant markers as for 
the IFN-γ expression (Chapter 4). The weakly IL-4-positive cells (IL-4low) were 
analysed by gating T cells as above and then CD8-positive and –negative cells in a 
CD8-FITC versus IL-4-PE plot. The IL-4+ cells in these gates were then plotted as 
histograms. The histogram of the cells labelled with control-PE antibody was 
overlaid on that of the IL-4 labelled cells and scaled to the same number of gated 
cells. Using the dedicated software, the control histogram was subtracted from the 
IL-4 histogram and the number of cells in the subtracted histogram was obtained 
from the histogram statistics after placement of an appropriate marker. 
 
5.2.4  Culture of Jurkat cells and preparation of cell lysate. 
 
Jurkat cells were cultured in RPMI 1640 medium with 5% FCS and penicillin and 
streptomycin at 106/ml with 1µg/ml BFA or the equivalent concentration of the 
solvent dimethyl sulphoxide (DMSO) overnight. After a sample was removed for 
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flow cytometry they were centrifuged and the cell pellets resuspended at 30x106/ml 
in cold lysis buffer consisting of 1.75% v/v Triton-X100 in 0.15M NaCl, 20mM 
sodium phosphate buffer pH 7.4 and 1% v/v protease inhibitor cocktail. After 30mins 
on ice the lysates were microfuged in the cold and the supernatants frozen at -80°C. 
Before testing in the IL-4 ELISA the lysates were diluted with an equal volume of 
lysis buffer without Triton-X. 
 
5.2.5  Statistical analysis 
 
Data for patients at diagnosis and control subjects were analyzed for significant 
differences from those for healthy subjects by means of the Mann-Whitney test 
whereas the Wilcoxon matched pairs test was used for the analysis of data for 
patients at diagnosis and at the end of treatment as well as data for stimulated and 
unstimulated cells (*: p=0.01-0.05, **: p=0.001-0.01, ***: p<0.001). 
  
5.3  RESULTS 
 
5.3.1  Intracellular IL-4 expression in T lymphocytes of TB patients. 
 
T cells and their CD8-positive and negative subsets were gated as in Fig. 5.1A. A 
small but a distinct strongly IL-4 positive T cell population was detected in blood 
from patients and healthy controls which could be accurately separated from the 
negative population (IL-4high, shown in Fig. 5.1B). The labelling was specific as it 
could be inhibited by pre-incubation of the mAb with recombinant IL-4 (comparable 
to that with isotype control-PE mAb, not shown). Background labelling with control 
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antibody was low, usually less than 50 events or 0.2% (Fig. 5.1B). The numbers of 
IL-4high cells in the CD8 population were mostly not significant, i.e. less that 100 
events, and were not analyzed. Significant numbers were however found in the CD8-
negative population, referred to as CD4 T cells, as they would comprise mainly 
CD4+  T cells but could also include some double-negative and NKT cells. When 
comparing the IL-4 antibody-labelled cells with the control antibody-labelled cells, it 
was apparent that all cell samples contained a large population that expressed low 
levels of IL-4 (IL-4low, shown in Fig. 5.1B) and overlapped with the negative 
population. Accurate percentages of these cells could not be obtained by the 
conventional method of analysis i.e. copying the quadrant marker from the control 
sample into the test sample, as the placement of the marker is subjective and small 
variations lead to large differences in the percentages of cells obtained. Therefore 
histogram subtraction according to the BD flow cytometry user manual was used to 
analyze these cells as described in Materials and Methods and shown in Fig. 5.1C. 
This mathematical method is absolutely objective and the results are only subject to 
some inaccuracy due to biological variation relating to the variable binding of the 
control antibody to different cell samples, which was greater in patients than in 
controls. 
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Figure 5.1 
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Figure 5.1:  A representative flow cytometric analysis showing the bimodal 
 hours 
expression of intracellular IL-4 by T cells from a TB patient at diagnosis. 
Whole blood was diluted 1:1 with RPMI+ medium prior to stimulation for 4
with anti-CD3 mAb at 0.1µg/ml, with BFA present for the last 3 hours. Labelling of 
intracelluar IL-4 and cell surface CD3 and CD8 was performed as described in 
Materials and Methods. The gating of CD3 T cells and CD8-positive and  
–negative subsets is shown in A and the IL-4high and IL-4low T cells in B. The 
histogram subtraction described in Materials and Methods, which was used to 
determine percentages of IL-4low CD4 and CD8 T cells, is illustrated in C where the 
shaded histogram represents the result of subtracting the control histogram (dotted 
line) from the IL-4 histogram (solid line). As the IL-4 histogram is bimodal and the 
control histogram unimodal, the subtracted histogram coincides almost exactly with 
the second peak of the IL-4 histogram. 
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Significant numbers of IL-4high CD4 T cells were not only found in the 
stimulated blood cultures but also in the unstimulated cultures of both patients and 
controls (shown for patients in Fig. 5.2A) and the percentages in the stimulated blood 
were significantly lower than in the unstimulated samples (p<0.05, Wilcoxon 
matched pairs test). In TB patients at diagnosis the percentages in unstimulated blood 
were higher (not significantly) than those in unstimulated blood of controls (Fig. 
5.2B) and there was a significant decrease in IL-4high CD4 T cells in patients between 
diagnosis and end of treatment at week 26 (p<0.01, Wilcoxon matched pairs test). 
Numbers of IL-4high  cells in the CD8 subset were mostly below the detection limit of 
the assay. 
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Figure 5.2:  High level IL-4 expression in the CD4 T cell subset. 
Expression in stimulated blood of patients at diagnosis is compared with that of 
unstimulated blood in Fig. 5.2A. The higher percentages in unstimulated blood are 
compared in controls, patients at diagnosis and at treatment end in Fig. 5.2B. 
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The percentages of IL-4low T cells in the CD4 T cell subset (Fig. 5.3A and B) 
and CD8 subset (C and D) were slightly higher or no different in stimulated 
compared to  unstimulated blood from patients and controls (shown for patients in A 
and C). Percentages of IL-4low CD4 T cells were lower than normal in stimulated 
blood from patients at diagnosis but at week 26 they were comparable to normal (B) 
whereas in CD8 T cells they were lower than normal in patients at diagnosis and at 
week 26 (D). Percentages in unstimulated blood were similar and are not shown. The 
differences were not statistically significant but p values close to 0.05 are given. 
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Figure 5.3 
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Figure 5.3:  Low level IL-4 expression determined by histogram subtraction. 
Percentages of IL4low T cells is shown for the CD4 subsets (A and B) and CD8 
subset (B and C). The differences between stimulated and unstimulated cells (shown 
for patients at diagnosis in A and C) are not significant (Wilcoxon matched pairs 
test). The percentages in stimulated blood of controls, patients at diagnosis and at 
week 26 are compared in B and D and are not significant (Mann-Whitney test). Near- 
significant p values close to 0.05 are shown. 
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When the patients were divided into fast and slow responder groups 
according to sputum culture positivity at week 8 (as in the previous chapters), and 
their IL-4low percentages compared, the fast responders had more IL-4low cells that 
the slow responders, both in the CD4 and CD8 subset (Fig. 5.4 A and B respectively) 
and the difference in the CD4 subset was significant (p<0.05, Mann-Whitney test). 
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Figure 5.4 
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Figure 5.4:  Low level IL-4 expression in fast and slow responder patients. 
IL-4low expression in stimulated T cells is compared by means of the Mann-Whitney 
test in fast responder and slow responder patients, defined by negative or positive 
sputum culture at week 8 respectively, in the CD4 T cell subset (A) and CD8 subset 
(B).  
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If the Th1/Th2 hypothesis were true for the cellular immune response to TB, 
patients’ T cells should produce more IL-4 in response to TCR stimulation than those 
of controls. Instead, constitutive bimodal intracellular IL-4 expression was found in 
both patients and controls in this study and the results were not explicable in this 
context. An alternative explanation had to be considered and is possibly offered by a 
previous report of an association of intracellular IL-4 expression with apoptosis of 
human lymphocytes [33]. This report showed co-labelling of cells with antibody to 
IL-4 and the apoptosis-related molecules Apo2.7 and Bcl-2. The authors did not 
investigate or postulate a mechanism of this IL-4 co-expression. If intracellular IL-
4high expression was an indicator of apoptosis this could explain the higher 
percentages of IL-4high cells in patients compared to controls as an increase in 
apoptotic cells has been found in the circulation of TB patients [45,46]. The present 
study has found, by kinetic studies and intracellular IFN-γ labelling after anti-CD3 
stimulation (Chapter 4) that TB patients at diagnosis have more pre-activated T cells 
in the circulation than controls. These cells, when cultured in vitro, would have a 
shorter lifespan and would go into apoptosis sooner than T cells from uninfected 
donors. Re-stimulation of these pre-activated cells could prolong their lifespan and 
this could explain why lower numbers of IL-4high T cells were found in the stimulated 
cultures. To substantiate this thinking, unstimulated blood from 3 new TB patients at 
diagnosis was labelled for IL-4 and active caspase-3, the main effector caspase in 
apoptosis, using the same 4-hour culture conditions and labelling method as for the 
main study. This showed that most of IL-4high T cells co-expressed active caspase-3 
(shown for one patient in Fig. 5.5).  
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Figure 5.5 
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Figure 5.5:  Co-expression of IL-4high  and active caspase-3 in T cells from a TB 
patient at diagnosis.  
Whole blood was incubated for 4 hours without stimulation as in Materials and 
Methods. CD3-PerCP expression was used to gate the T cells of which the IL-4-PE 
(or control-PE) co-labelling with caspase-3-FITC is shown. The quadrant marker 
from the control-PE plot was copied into the caspase-3-FITC versus IL-4-PE plot. 
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To obtain additional evidence for the association of IL-4 expression with 
apoptosis induced by in vitro culture, whole blood from a healthy laboratory staff 
volunteer was diluted 1:1 with RPMI+ medium as in the tests of patients, but was 
incubated at 37°C in 5% carbon dioxide overnight in the presence of 5µg/ml BFA, 
which has been shown to induce apoptosis in the Jurkat T cell line [79], or the 
solvent dimethyl sulphoxide (DMSO). The leukocytes were then labelled for 
intracellular IL-4 and active caspase-3, using the method that includes a fixation step 
to obtain better flow cytometric separation of lymphocytes from neutrophils and 
monocytes by light scatter characteristics. As shown in Fig. 5.6, the T cells, gated by 
their low side scatter and CD3 expression, showed a clear population that co-
expressed IL-4 and caspase-3. 
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Figure 5.6 
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Figure 5.6:  Induction of apoptotic T cells by prolonged culture with BFA. 
Whole blood from a healthy volunteer was diluted 1:1 with RPMI+ medium and was 
incubated in polypropylene tubes for 24 hours at 37°C and 5% CO2 in the presence 
of 5µg/ml BFA (DMSO for the control). Leukocytes were then labelled for IL-4 and 
active caspase-3 as described in Materials and Methods, using the method that 
includes a fixation step. The gating according to low side scatter and CD3 expression 
is shown in A and IL-4 and caspase-3 co-expression in B. As a negative control for 
the specificity of the IL-4 labelling, 5µg recombinant IL-4 was added to the IL-4 
antibody 15 minutes before the addition to the cells. The quadrant marker from this 
plot was copied into the other two plots in B. 
 89
5.3.2  Co-expression of intracellular IL-4 and active caspase-3 in Jurkat cells 
 
To find further evidence of the association of IL-4 with apoptosis, the Jurkat T cell 
line was chosen for supplementary experiments. It has been shown that apoptosis is 
readily induced in these cells by low concentrations of BFA [79]. After incubating 
the cells with BFA at 1µg/ml for 24 hours the cells were labelled for IL-4 and active 
caspase-3. Live and apoptotic cells were gated in light scatter dot plots as shown in 
Fig. 5.7A. Co-expression of high levels of IL-4 and active caspase-3 is shown in Fig. 
5.7B where 40.9% of BFA-treated cells  and only 1.5% of the control cells, treated 
with only the solvent DMSO, co-expressed these molecules. The quadrant marker 
was copied from the plot showing the IL-4 labelling inhibited by the addition of 
recombinant IL-4. The BFA-treated cells that expressed only caspase-3 could be in a 
more advanced stage of cell death. 
An alternative method of inducing apoptosis in cells is culture in medium 
containing low concentrations of serum. Jurkat cells were cultured overnight in 
medium containing 0.5% FCS instead of the normal 5% and labelled for IL-4 and 
caspase-3 (Fig. 5.7C). The number of IL-4+ cells was 3% in 0.5% serum and 0.9% in 
5% serum and the majority of the IL-4+  cells co-expressed active caspase-3. 
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Figure 5.7 
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Figure 5.7:  Expression of intracellular IL-4 and active caspase-3 in Jurkat cells. 
The cells were gated in a light scatter plot shown in (A) to include both the high FSC 
viable cells and the low FSC apoptotic cells. The IL-4/caspase-3 co-expression is 
shown in (B) for cells treated for 24 hours with BFA at 1µg/ml and control cells 
treated with DMSO. The addition of recombinant IL-4 to the IL-4 antibody before 
addition to the cells abolished the labelling, confirming the specificity of antibody 
binding. In (C) the co-expression of IL-4 and caspase-3 is shown in Jurkat cells 
incubated for 24 hours in 0.5% FCS and control cells grown in 5% FCS. 
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To confirm the findings in Jurkat cells an alternative method, i.e. ELISA, was 
chosen to show the IL-4 production by these cells. Jurkat cells were incubated for 24 
hours in the presence of 1µg/ml BFA or an equivalent concentration of DMSO and 
approximately 1ml of the spent culture supernatants saved. Detergent lysates of the 
cells were prepared which were subsequently tested by means of a high sensitivity 
IL-4 ELISA kit. A sample of the cells was also labelled for flow cytometry and the 
results were comparable to those shown in Fig. 5.7. The ELISA showed just 
detectable levels of secreted IL-4 of 0.30pg/ml in the control supernatant but not in 
the cell lysate. In the BFA-treated culture secreted IL-4 was undetectable 
(<0.25pg/ml) but in the cell lysate 1.55pg/ml IL-4 was detected, thus confirming the 
intracellular staining results (summarized in Table 5.1). A repeat experiment gave 
similar results.  
 
 
Table 5.1: Parallel tests for IL-4 in Jurkat cells by flow cytometry and ELISA 
 Flow cytometry 
(% IL-4high  cells) 
ELISA (pg/ml) 
  Supernatant Lysate 
Control 1.8 0.30 <0.25 
BFA 50.6 <0.25 1.55 
 
 
5.3.3  Expression of intracellular IL-4 by apoptotic neutrophils 
 
During the flow cytometric data acquisition of the whole blood samples it was 
apparent that a subset of neutrophils, which die rapidly when cultured in vitro, were 
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labelled by the IL-4 antibody. The expression of IL-4 in neutrophils has been 
reported before [73] and it has also been shown that BFA increases the constitutive 
apoptosis of human neutrophils [80]. To investigate if the co-expression of IL-4 and 
caspase-3 holds true for neutrophils as well, whole blood was diluted with an equal 
volume of RPMI+ medium in polypropylene tubes as for the main study but was 
incubated in a 37° incubator with 5% carbon dioxide overnight in the presence of 
5µg/ml BFA (as for Fig. 5.6). The blood cells were labelled for flow cytometry using 
the method with a fixation step to preserve the light scatter characteristics of the 
neutrophils and monocytes for gating as shown in Fig. 5.8A. Monocytes in cultured 
blood have similar light scatter to neutrophils which were separated from monocytes 
by their lack of DR expression. The number of IL-4high cells, which co-expressed 
active caspase-3, was increased in the BFA-treated cells and a smaller population 
expressed only caspase-3 (Fig. 5.8B). The addition of recombinant IL-4 to the anti-
IL-4 antibody before reaction with the cells inhibited the antibody binding, thus 
confirming the specificity of the labelling. The quadrant marker in this plot was 
copied into the other plots of Fig. 5.8B.  
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Figure 5.8 
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Figure 5.8:  Expression of intracellular IL-4 and active caspase-3 in peripheral 
blood neutrophils. 
Whole heparinized blood from a healthy control was diluted 1:1 with RPMI+ 
medium and incubated 24 hours with 5µg/ml BFA in polypropylene tubes. 
Intracellular IL-4, active caspase-3 and cell surface HLA-DR were labelled as 
described in Materials and Methods with the inclusion of a fixation step to preserve 
the light scatter characteristics of neutrophils and monocytes. Neutrophils were gated 
as shown in A by their high SSC and lack of HLA-DR-APC binding and then 
analyzed for IL-4 and caspase-3 co-expression (B). For the control IL-4 labelling was 
inhibited by the addition of recombinant IL-4. The quadrant marker from the control 
plot was copied into the other plots. 
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5.3.4  Expression of intracellular IL-4 by apoptotic monocytes 
 
As Pouliot et al [74] demonstrated IL-4 protein and mRNA expression in alveolar 
macrophages of all their normal test subjects and asthma patients, peripheral blood 
monocytes were included in the analysis of whole blood incubated in the presence of 
5µg/ml BFA for 24 hours. Monocytes in the high side scatter population were 
separated from neutrophils by their DR expression (Fig. 5.9A) and labelled for IL-4 
and caspase-3 (Fig. 5.9B). In the DMSO control most monocytes produced low 
levels of IL-4 and a low percentage produced high levels and co-expressed  
caspase-3. In the BFA-treated blood the IL-4high cells co-expressed caspase-3  and 
there was also a significant  population that expressed caspase-3 only. The quadrant 
marker in the control plot, where IL-4 labelling was inhibited by recombinant IL-4, 
was copied into the other plots in Fig. 5.9B. 
 97
Figure 5.9 
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Figure 5.9:  Expression of IL-4 and active caspase-3 by peripheral blood 
monocytes. 
Heparinized whole blood from a healthy control was incubated with BFA and 
labelled with mAbs as for Fig. 5.8. Monocytes were gated by their high SSC and 
HLA-DR expression as shown in A and then analyzed for IL-4 and caspase-3 co-
expression with the control as in Fig. 5.8. DR expression is down regulated in 
apoptotic monocytes but still sufficient for gating. 
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5.3.5  Stimulation of neutrophils and monocytes decreases IL-4high  expression 
 
As lipopolysaccharide (LPS) is known to save neutrophils from apoptosis [81], IL-4 
expression in neutrophils and monocytes in whole blood treated with 50pg/ml LPS 
overnight was compared with that in untreated cells, shown in Fig. 5.10. As for Figs 
5.8 and 5.9, the high SSC cells were separated into neutrophils and monocytes by 
their DR expression. The percentage of IL-4high  neutrophils and monocytes, shown 
in the relevant quadrants, was markedly lower in the LPS-treated blood than in the 
control suggesting that stimulation of these cells delays their apoptosis in vitro. 
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Figure 5.10 
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Figure 5.10:  Inhibition of intracellular IL-4 expression in neutrophils and 
monocytes by stimulation with LPS. 
Heparinized whole blood from a healthy control was diluted 1:1 with RPMI+ 
medium in polypropylene tubes and stimulated overnight with 50pg/ml LPS. 
Leukocytes were labelled with IL-4-PE and HLA-DR-FITC using the method with a 
fixation step. Monocytes and neutrophils in the high SSC population were gated 
according to whether they expressed HLA-DR or not, respectively, and the 
percentages of IL-4+ cells compared. Active caspase-3 was not labelled in these cells. 
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5.4  DISCUSSION 
 
As outlined in the introduction, attempts to prove the Th1/Th2 hypothesis in the 
clinical setting of tuberculosis have not been very conclusive which may, in part, be 
due to the fact that many cells express IL-4 receptors and IL-4 secreted by cells into 
the medium during in vitro culture may be consumed by the same or other cells in an 
autocrine or paracrine manner. The detection of mRNA for IL-4 does not necessarily 
indicate that the cytokine is expressed and secreted, as was shown in human B 
lymphocytes and lymphoid cell lines [76]. An additional confounding factor is the 
existence of an alternatively spliced form of IL-4, IL-4δ2 [82], that acts as a 
competitive antagonist binding to the α chain of the IL-4 receptor and cannot be 
distinguished from IL-4 by currently available antibodies. 
Secreted IL-4 has been detected by ELISA in the medium of PHA- or 
PMA+ionophore-stimulated PBMCs [76], Mtb sonicate-stimulated and unstimulated 
PBMCs [56], and PBMCs stimulated with Mtb recombinant antigens and peptides 
[68], as well as by ELISPOT in Mtb antigen-stimulated PBMCs [67]; IL-4 mRNA 
could also be detected in ex vivo unstimulated PBMCs [45,46,83]. In a recent report 
it was shown that IL-4 acts as an autocrine growth factor in dendritic cells [75]. The 
authors detected very low levels in the cells by means of an amplification step in 
their labelling protocol and rarely detected it in the medium as a result of its binding 
to cell surface receptors. 
With the methods used here such low level secretion could just be detected in 
spent medium of Jurkat cells with a very sensitive ELISA assay, and for the detection 
of intracellular IL-4 by flow cytometry a specially optimized labelling protocol was 
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used in which the addition of 3% PEG to the buffers achieved additional sensitivity 
when compared to buffers without PEG (not shown). Intracellular IL-4 was also 
detected in unstimulated T cells as did Dlugovitzky et al [56] in unstimulated 
supernatants. A comparison of labelled peripheral blood lymphocytes from a patient 
in ex vivo blood with those in 4-hour stimulated blood showed the presence of IL-
4low  but not  IL-4high T cells in the ex vivo blood (not shown), suggesting that the low 
intracellular IL-4 levels are steady-state levels of IL-4 whereas  IL-4high T cells are 
cells that are induced by in vitro culture. The percentages of IL-4low T cells in 
patients tested at diagnosis in this study were lower than in control subjects and 
lower than in the patients at the end of treatment. They were also lower in the 
patients that responded more slowly to treatment. This suggests that this IL-4 
production is an advantage and would confirm a growth factor function for IL-4 in 
the response to Mtb infection.  
The bimodal expression of intracellular IL-4 has, to my knowledge, not been 
reported before but IL-4 has been associated with apoptosis [33]. Apoptosis is cell 
death that occurs naturally during tissue turnover and after activation in the terminal 
phase of the cell-mediated immune response. In lymphocytes it is triggered by either 
the engagement of death receptors, such as Fas, or by cytokine withdrawal (reviewed 
in [7]). Signals from death receptors are transmitted via an intracellular signalling 
complex involving adaptor molecules while cytokine withdrawal initiates stress-
induced signals within the cell that are transmitted via the mitochondria and the Bcl-
2 family proteins. Both these pathways lead to the activation of caspases, with 
caspase-3 being a key player in the effector phase and the loss of cell integrity.  
The demonstrated co-expression of high levels of IL-4 with active caspase-3 
in a subset of peripheral blood T lymphocytes, neutrophils and monocytes and in 
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Jurkat cells indicates that these cells are in the process of apoptosis. This is in 
agreement with the findings of Stein et al [33] who demonstrated the co-expression 
of IL-4 and the apoptosis-associated molecule Apo2.7 in PBMC, the T cell line 
MOLT-4 and the monocytic line THP-1 after inducing apoptosis with a variety of 
drugs. Like these authors, it was found here that the kinetics of the co-expression of 
IL-4 and caspase-3 vary in the different cell types, the co-expression in lymphocytes 
being longer than in neutrophils or monocytes, with a greater likelihood of detecting 
it at the end of the culture period. 
The findings of this study have led me to postulate that IL-4 is produced as an 
autocrine/paracrine growth factor in various cell types and that the secretion ceases at 
the onset of apoptosis as a result of a stimulus or lack of a stimulus which could be 
either a soluble factor or a ligand(s) on the surface of other cells. Intracellular 
accumulation of IL-4 then takes place during the apoptotic process until cell death. 
The neutrophils labelled for IL-4 shown in Fig. 5.10 were not treated with BFA to 
stop secretion of the cytokine which would support this view. Whether the 
accumulated intracellular IL-4 is released into the medium by dead cells before their 
engulfment by phagocytic cells is unknown. If IL-4 is an essential growth factor, my 
finding that T cells with constitutive low level production of IL-4 were reduced in 
TB patients at diagnosis when compared to those from healthy controls, may indicate 
impaired function. The higher numbers of apoptotic cells that express higher levels 
of IL-4 in patients is in line with previous findings of increased numbers of apoptotic 
T cells in the blood TB patients [45,46]. 
In summary, the presented data relating to intracellular IL-4 expression and 
the conflicting large volume of published data of IFN-γ production by T cells of TB 
patients (reviewed in Chapter 4) suggests that a reconsideration of the role of IL-4 is 
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warranted and that a continued search for other defects of cell-mediated immunity in 
these patients is needed. 
 
6.  GENERAL DISCUSSION 
  
The findings of this thesis have pointed out several important aspects in the study of 
immune parameters during active TB disease which have to be taken into 
consideration when performing similar investigations.  
The immune cells of the TB patients are in an abnormal state and accurate 
comparisons of test results for patients at or soon after diagnosis, when the bacterial 
load is high, cannot be made with those from healthy subjects. The results of tests 
performed in this study changed rapidly within the first few weeks of treatment and 
if groups of patients are tested, this has to be done at accurately matched time points 
after start of treatment. In this study, with the exception of the absolute monocyte, 
NK and NKT cells counts, the parameters in patients at treatment end were 
comparable to normal subjects.  
The immunophenotyping was found to be an accurate and reproducible test 
and the detection of a novel NKT cell subset should be confirmed and their 
significance investigated in larger number of patients. Phenotyping is also a 
relatively low cost and quick assay and may therefore be more useful in large scale 
applications. 
The stimulation of patients’ blood in in vitro culture and the measurement of 
cytokine production and proliferation is complicated by the abnormal immune status 
of the patients in that they seem to have relatively large numbers of cells previously 
activated by mycobacterial antigens which, when re-activated, rapidly progress 
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towards apoptosis, after which no more functional assays can be done on them. The 
obvious cell clumps in blood of TB patients at diagnosis stimulated with live Mtb or 
PPD that I observed in optimization experiments for this study pointed out this 
problem. This was also shown experimentally in vitro by Soruri et al [84] who 
produced PPD-activated T cells in culture and then re-activated them. They found 
that re-activation with PPD caused apoptosis in a concentration-dependent manner 
and the authors postulate that this happens in vivo in caseous tuberculous granulomas 
in the lungs. To my knowledge, the variation in the kinetics of IFN-γ production has 
not been shown before, and could partially explain the extremely variable results and 
paradoxes that characterize the investigations of this essential cytokine, illustrated in  
Tables 4.1, 4.2 and 4.3 (pages 43-44) compiled from my literature search. The results 
of this study indicate that the intracellular IFN-γ assay after a short stimulation of 
approximately 6 hours may be helpful in the identification of Mtb-infected 
individuals. 
The role of IL-4 in the context of the Th1/Th2 hypothesis, analogous to its 
role in the mouse, but not proved in human TB, could not be confirmed in this study. 
On the contrary, the results point to a beneficial and normal function of  
IL-4 as a growth factor and an interesting mechanism of secretion or retention of this 
cytokine in various cell types in response to apoptosis-inducing conditions. The 
demonstration of high levels of intracellular IL-4 expression after a relatively short 
exposure to BFA leads one to cautious interpretation of results of assays that measure 
the intracellular expression of this cytokine in which BFA is usually added to 
cultures to prevent the secretion of the cytokine. 
In summary, regarding the hypothesis formulated for this study, point (1) of 
the alternative hypothesis can be said to be true for patients at diagnosis when their 
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immune responses were found to be abnormal. At the end of treatment, when there 
was no evidence of infection, they were essentially normal. The exceptions of the 
low absolute monocyte, NK and CD3bright NKT cell counts at the end of treatment 
could be an effect of the treatment itself. Point (2) of the alternative hypothesis was 
found not to be true for the conventional immune parameters but was true for a 
newly described NKT cell subset and possibly constitutive production of IL-4 by T 
cells of patients at diagnosis. Both these are, to my knowledge, new findings and 
would have to be confirmed by more investigations on larger numbers of patients. 
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8.  APPENDIX 
 
8.1  SUPPLIERS OF REAGENTS 
 
BD-Biosciences (Erembodegem, Belgium).  
ATCC (Rockville, MD, USA) 
Gibco-BRL (Paisley, Scotland), 
Sigma (Kempton Park, South Africa).  
R&D Systems (Minneapolis, US)  
Beckman Coulter (Johannesburg, South Africa),  
Merck (Cape Town, South Africa). 
 
8.2  SOLUTIONS 
 
Phosphate-buffered saline (PBS):  
NaCl    8.0g 
KCl    0.2g 
Na2HPO4.2H2O  1.44g  per litre 
KH2PO4    0.24g 
NaN3    0.5g 
 
Lyse/wash buffer:  
PBS containing 0.05% saponin and 3% PEG 4000 
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RPMI+ 
RPMI 1640 medium (Gibco) with GlutaMAX, bicarbonate and 25mM HEPES, to 
which 100µg/ml Streptomycin, 100U/ml Penicillin and 50µM 2-Mercaptoethanol is 
added just before use. The same medium, but without HEPES, was used for the 
overnight incubations, the culture of Jurkat cells and the lymphocyte proliferation.  
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Summary
 
The immune responses against pulmonary tuberculosis are still poorly
defined. This study describes changes in leucocyte and lymphocyte subsets
during treatment to find reliable immunological markers for the disease and
treatment response. Flow cytometric peripheral blood immune phenotyping,
routine haematology and sputum microbiology were performed on 21 HIV-
negative adult tuberculosis (TB) patients with positive sputum cultures dur-
ing therapy in comparison with 14 healthy purified protein derivative (PPD)-
positive volunteers. Patients at diagnosis showed high absolute neutrophil
and monocyte counts which fell during treatment but low lymphocyte subset
counts which increased [except natural killer (NK) and NK T cells]. High
counts of a population of CD3
 
dim
 
/CD56
 
+
 
 NK T cells at diagnosis correlated sig-
nificantly with negative sputum culture after 8 weeks of treatment. A multi-
variate classification technique showed improved correlation when NK cells
were taken into account. In conclusion, peripheral blood white cell counts
change significantly during treatment and counts at diagnosis, especially
CD3
 
dim
 
/CD56
 
+
 
 NK T cells, hold promise in predictive models of TB treatment
response.
 
Keywords:
 
 immunophenotyping, NK T cells, treatment response, tuberculosis 
 
Introduction
 
The mechanisms of protective immunity against 
 
Mycobacte-
rium tuberculosis
 
 (Mtb) infection and disease in humans
have not been fully clarified. Many reports have addressed
the potential immunological defect(s) by comparing
immune phenotypes in actively diseased patients to those
with latent infection. Most of these investigations have
focused on T lymphocyte subsets, particularly CD4
 
+
 
 and 
 
γδ
 
T cells, generally reporting depressed CD4
 
+
 
 T cells in periph-
eral blood of tuberculosis (TB) patients [1–3], but results are
discrepant for 
 
γδ
 
 T cells, where both elevated [4,5] and nor-
mal [6,7] numbers have been found. Only a few but incon-
clusive reports of B lymphocyte and natural killer (NK) cell
numbers in TB patients exist [1,3,8,9] and NK T cells have, to
our knowledge, not been investigated in TB patients. Gener-
ally, contributors to TB susceptibility remain unclear and
follow-up data during therapy are scanty.
The aim of our study was to investigate immune param-
eters during therapy and this report describes a systematic
follow-up of leucocyte counts and lymphocyte subsets in
TB patients for the entire 26-week treatment period.
Furthermore, due to the fact that the identification of high-
risk patients for slow response to chemotherapy would have
important clinical implications, we analysed peripheral
blood immunophenotypes as potential surrogate markers of
early TB treatment response and applied a multivariate clas-
sification technique to identify fast and slow responders to
treatment by immunophenotype at diagnosis.
 
Materials and methods
 
Setting
 
This study was conducted in an epidemiological field site in
metropolitan Cape Town, where the incidence of new smear
and/or culture-positive TB was on average 313/100 000
population/year (1993–98) [10].
 
Patients and controls
 
The study was approved by the Ethics Committee of the Fac-
ulty of Health Sciences at Stellenbosch University and writ-
ten, informed consent was obtained from all participants.
 Lymphocyte subsets during TB treatment
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Twenty-nine new smear-positive pulmonary TB patients
were screened for this study. Inclusion criteria included:
sputum culture-positive for Mtb, no multi-drug resistance,
HIV-negative, taking at least 80% of prescribed doses during
the intensive phase of treatment. Eight patients were
excluded for the following reasons: non-compliance, multi-
drug-resistant TB, negative sputum culture, refusal of HIV
testing or incomplete follow-up visits. Twenty-one patients
with first-time TB were enrolled and studied throughout
treatment. Blood samples were taken at diagnosis prior to
initiation of treatment and at weeks 1, 5, 13, and 26 after start
of treatment (the last blood sample being taken on the last
day of chemotherapy). Sputum smears and Bactec cultures
were performed on days 1 and 3, and weeks 1, 2, 4, 8, 13 and
26 after start of treatment. A total white cell count (WCC)
and differential blood count was performed on all blood
samples using a Bayer Advia 120. The patients received stan-
dard therapy in accordance with the South African National
Tuberculosis Program [based on World Health Organization
(WHO) guidelines]. Therapy consisted of a fixed drug com-
bination (depending on body weight) containing isoniazid
(320–400 mg/day), rifampicin (480–600 mg/day), ethambu-
tol (800–1200 mg/day) and pyrazinamide (1000–1250 mg/
day) during the intensive phase (8 weeks) followed by
rifampicin and isoniazid during the continuation phase (the
remaining 18 weeks) under direct observation. Posterior–
anterior and lateral chest X-rays (CXR) were taken at com-
mencement of treatment allowing a 4-week time window on
either side of diagnosis. The chest radiographs were evalu-
ated using a standardized method [11] by a physician who
had no prior knowledge of the patient’s condition. The
extent of disease was estimated using a one-dimensional
view of the upright posterior–anterior radiograph and by
using the right upper lobe as reference area.
One blood sample was taken from each of 14 healthy HIV-
negative, purified protein derivative (PPD) skin test-positive
(
 
>
 
 15 mm) volunteers resident in the same community to
serve as controls. These participants had no clinical or radio-
logical signs of active TB.
 
Processing of sputum samples for Ziehl–Nielsen smear 
and culture
 
Sputum samples were processed for culture using standard
methods [12], which included decontamination according
to the Bactec 460TB System Procedure Manual (Becton
Dickinson, Sparks, MD, USA) before inoculation into a
Bactec 12B vial. The vials were incubated at 37
 
°
 
C and the
growth index (GI) was read daily. Sputum smears, direct
and concentrated, were examined for acid-fast bacilli using
the Ziehl–Nielsen (ZN) stain and evaluated using the scor-
ing system of the International Union against Tuberculosis
and Lung  Disease  [13].  If  multiple  smears  were
performed  the smear with the highest grade was recorded
for that time-point.
 
Reagents
 
Fluorochrome-labelled monoclonal antibodies (mAb) anti-
CD45-peridinin chlorophyll (PerCP), CD3-phycoerythrin
(PE), CD3-PerCP, CD4-fluorescein isothiocyanate (FITC),
CD8-FITC, CD19-FITC, CD56-FITC, 
 
γδ
 
 T cell receptor
(TCR)-FITC, interferon (IFN)-
 
γ
 
-PE, interleukin (IL)-4-PE
and rabbit anti-active caspase 3-FITC were from BD-
Bioscience (Erembodegem, Belgium). A rabbit FITC control
antibody was not available from the manufacturer. OKT3
anti-CD3 antibody was spent hybridoma medium. The
hybridomas were from the American Type Culture Collection
(ATCC, Rockville, MD, USA). V
 
α
 
24-PE was purchased from
Beckman Coulter (Johannesburg, South Africa), saponin
from Sigma (Kempton Park, South Africa) and polyethylene
glycol 4000 (PEG) from Merck (Cape Town, South Africa).
 
Immunophenotyping by flow cytometry
 
Whole blood (50 
 
µ
 
l per test), anti-coagulated with sodium
heparin, was washed once with phosphate-buffered saline
(PBS), suspended in 100 
 
µ
 
l of 0·1% bovine serum albumin
(BSA), 0·05% sodium azide in PBS and added to the
required antibody mixtures. After 20 min at 4
 
°
 
C, cells were
washed and red blood cells (RBCs) lysed at the same time
by diluting with 3–4 ml cold PBS containing 0·05% sapo-
nin, 0·05% sodium azide and 3% PEG. (We have noted pre-
viously that RBCs in whole blood from TB patients
frequently failed to lyse when treated with commercial lys-
ing solution and therefore used saponin as alternative lysis
solution. The addition of 3% w/v PEG to the saponin buffer
prevents damage and clumping of cells  in blood obtained
at diagnosis and also enhances the formation of antigen/
antibody complexes [14]). After centrifugation at 700 
 
g
 
 the
cell pellets were fixed in 4% formaldehyde in PBS and
stored at 4
 
°
 
C in the dark until flow cytometric analysis in a
Becton-Dickinson fluorescence activated cell sorter
(FACS)Calibur using CellQuest software. Lymphocytes were
gated in a CD45-PerCP 
 
versus
 
 side scatter plot (10 000
events in this gate were acquired) and these were analysed
further for expression of CD3 and CD4 (or CD8, CD19,
CD56, 
 
γδ
 
TCR) in the FL1 and FL2 channels, respectively.
The lymphocyte sums calculated were all between 95 and
100%. Isotype control antibodies were not used routinely as
the background cell surface staining of 
 
ex vivo
 
 blood lym-
phocytes is very low (not shown).
 
Intracellular cytokine labelling
 
Briefly, whole heparinized blood was mixed 1 : 1 with RPMI-
1640 medium with antibiotics in polypropylene tubes and
incubated at 37
 
°
 
C with or without 0·1 
 
µ
 
g/ml OKT3 antibody
for 4 h, with 10 
 
µ
 
g/ml Brefeldin A present during the last 3 h.
After incubation the blood was diluted with cold PBS con-
taining 0·05% saponin, 0·05% sodium azide and 3% PEG
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(lyse/wash buffer), centrifuged in the cold at 700 
 
g
 
, and the
cells in the pellet were labelled with mAbs in the above buffer
containing 0·1% BSA for 20 min in the cold. After one wash
with cold lyse/wash buffer, the cell pellets were fixed in 4%
formaldehyde in PBS and analysed in the flow cytometer.
 
Classification of patients into treatment response groups
 
In order to find possible differences between fast and slow
responders to treatment, patients were divided into two
responder groups according to Bactec culture status at week
8 after start of treatment. Of the 21 enrolled patients eight
were culture-negative (fast responders) and 13 culture-
positive (slow responders).
 
Statistical analysis
 
Data for patients at diagnosis and at the end of treatment
were analysed for significant differences from those for
healthy  subjects  by  means  of  the  Mann–Whitney  test.
The Friedman test with Dunn’s post-test was used to analyse
longitudinal changes in parameters with respect to the
diagnosis  time-point  values  (*  or  #:  
 
P
 
 
 
=
 
 0·01–0·05,  **  or
##: 
 
P
 
 
 
=
 
 0·001–0·01, *** or ###: 
 
P
 
 
 
<
 
 0·001; asterisks refer to
the Mann–Whitney test and hashes to the Friedman test).
The Pearson 
 
χ
 
2
 
 test and Fisher’s exact test were used to
analyse categorical CXR data.
To find the best combination of variables at diagnosis that
may have potential for the prediction of early treatment
response,  as  defined  by  the  week  8  Bactec  sputum
culture,  a support vector machines analysis was performed,
a multivariate discriminant classification technique that has
received much attention in the statistical literature in the past
few years [15]. Combinations of up to a maximum of five
variables were analysed and, using the variables included in
the optimal classification model, a leave-one-out cross-
validation table was constructed.
 
Results
 
Demographic data of study population
 
The 21 patients were all cured after 26 weeks of standard
directly observed treatment short course (DOTS) therapy.
Three patients were infected with an Isoniazid-monoresis-
tant strain of mycobacteria. After 8 weeks of treatment 15
patients were smear-negative and six were smear-positive,
while only eight were culture-negative and 13 culture-
positive (two of these were Isoniazid-monoresistant). The
week 8 Bactec culture was therefore used as the more sensi-
tive indicator of early treatment response. No significant dif-
ferences between fast and slow responders in CXR findings at
diagnosis were found (including extent of disease and pres-
ence, number or size of cavities). The age and sex distribu-
tion of patients is given in Table 1.
 
Longitudinal changes in total and differential WCC
 
The total WCC and absolute neutrophil counts were signifi-
cantly elevated in patients at diagnosis relative to controls
(Fig. 1a,b) but returned to normal levels by the end of treat-
ment. The absolute monocyte counts were also significantly
elevated at diagnosis but then dropped dramatically to sig-
nificantly depressed levels at week 26 (Fig. 1c). The absolute
lymphocyte count of patients at diagnosis was significantly
depressed at diagnosis, but counts were no longer signifi-
cantly different from controls at the end of treatment
(Fig. 1d).
 
Lymphocyte subsets
 
Percentages of T lymphocytes and NK cells were not signif-
icantly different from those of controls at diagnosis or at
week 26, while percentages of B lymphocytes were depressed
in patients at diagnosis (
 
P
 
 
 
<
 
 0·05) and recovered during
treatment (not shown). The absolute lymphocyte subset
counts were calculated from the subset percentages and
absolute lymphocyte counts (Fig. 2). The absolute CD3
 
+
 
 T
cell and absolute CD19
 
+
 
 B cell counts were significantly
depressed in patients at diagnosis, but at week 26 these were
not significantly different from those of control subjects
(Fig. 2a,b). Absolute CD56
 
+
 
/CD3
 
–
 
 NK cell counts at diagno-
sis showed a trend towards lower numbers (
 
P
 
 
 
=
 
 0·06) and
remained depressed until week 26 (
 
P
 
 
 
<
 
 0·05, Fig. 2c).
 
T lymphocyte subsets
 
The percentages of CD4
 
+
 
, CD8
 
+
 
 and 
 
γδ
 
 T cells and the
CD4 : CD8 ratio at diagnosis and at week 26 were not sig-
nificantly different from those of control individuals and
only small fluctuations were detected during follow-up. We
detected two populations of NK T cells that differed in their
levels of expression of CD3: a CD56
 
+
 
 cell population which
expressed CD3 levels comparable to conventional T cells
(CD3
 
bright
 
/CD56
 
+
 
 NK T cells) and one that expressed reduced
levels (CD3
 
dim
 
/CD56
 
+
 
 NK T cells). The percentages of
CD3
 
bright
 
/CD56
 
+
 
 NK T cells in patients at diagnosis and at
week 26 were not significantly different from those of
controls (not shown) and CD3
 
dim
 
/CD56
 
+
 
 NK T cells are
described in detail below. Absolute numbers of T cell subsets,
calculated from the absolute lymphocyte count and the
 
Table 1.
 
Age and sex data of patients and controls.
Patients
ControlsFast responders
 
a
 
Slow responders
Total (no.) 8 13 14
Male (no.) 3 9 3
Female (no.) 5 4 11
Age (years) 18–51 19–50 20–56
 
a
 
As defined by negative sputum culture at week 8.
 Lymphocyte subsets during TB treatment
 
© 2006 British Society for Immunology, 
 
Clinical and Experimental Immunology
 
, 
 
145:
 
 252–260
 
255
 
percentages determined by immunophenotyping are illus-
trated in Fig. 3. CD4
 
+
 
 T cell numbers (Fig. 3a) were signifi-
cantly depressed at diagnosis relative to control subjects
(
 
P
 
 
 
<
 
 0·01) and, while numbers increased significantly during
treatment, they were still lower at week 26 than in controls
(
 
P
 
 
 
=
 
 0·06). CD8
 
+
 
 T cell counts were lower at diagnosis,
although not significantly so (Fig. 3b, 
 
P
 
 
 
=
 
 0·13) and 
 
γδ
 
 T cell
counts were significantly depressed (Fig. 3c, 
 
P
 
 
 
<
 
 0·05) but
both subsets recovered during treatment to normal levels at
week 26. Absolute numbers of CD3
 
bright
 
/CD56
 
+
 
 NK T cells
were lower at diagnosis (
 
P
 
 
 
=
 
 0·06) and were significantly low
at the end of treatment (
 
P
 
 
 
<
 
 0·05, Fig. 3d).
 
Fig. 1.
 
Absolute leucocyte counts of healthy control subjects and tuber-
culosis (TB) patients, calculated from the total white cell count and 
differential blood count. (a) Total white cell count (WCC), (b) neutro-
phils, (c) monocytes, (d) lymphocytes. The boxes extend from the 25th 
to the 75th percentile with a line at the median and the whiskers show 
the highest and lowest values. Data for patients at diagnosis (Dx) and 
at the end of treatment at week 26 were analysed for significant differ-
ences from those for healthy subjects by means of the Mann–Whitney 
test (*
 
P
 
 
 
<
 
 0·05, **
 
P
 
 
 
<
 
 0·01, ***
 
P
 
 
 
<
 
 0·001). The Friedman test with 
Dunn’s post-test was used to analyse changes in parameters during the 
patients’ follow-up with respect to values at diagnosis (#
 
P
 
 
 
<
 
 0·05, 
##
 
P
 
 
 
<
 
 0·01, ###
 
P
 
 
 
<
 
 0·001).
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Fig. 2. Absolute lymphocyte subset counts of healthy control subjects 
and tuberculosis (TB) patients, calculated from the absolute lymphocyte 
counts and the percentages of subsets determined by flow cytometric 
immunophenotyping. (a) T lymphocytes (CD3+), (b) B lymphocytes 
(CD19+), (c) natural killer (NK) cells (CD3–CD56+). Box and whisker 
plots and statistical analyses as for Fig. 1 (Mann–Whitney test *P < 0·05, 
**P < 0·01, ***P < 0·001, Dunn’s post-test #P < 0·05, ##P < 0·01, 
###P < 0·001).
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A CD3dim/CD56+ NK T cell subset was more prominent 
in patients
We detected an unusual subset of lymphocytes more fre-
quently in patients (nine of the 21 patients had ≥ 2% at diag-
nosis) than in controls (two of 14 had ≥ 2%). In the flow
cytometric analyses, of which Fig. 4 is an example, these cells
were weakly CD3+ (CD3dim), CD4–, weakly CD8+ or CD8–
and CD56+, shown in region R2 in Fig. 4d, and also γδTCR–
(not shown). The number of cells in region R2, as illustrated
in Fig. 4, expressed as a percentage of the cells in the CD45
gate, was determined for all blood samples. Figure 5a shows
increased percentages of CD3dim/CD56+ NK T cells in
patients at diagnosis relative to control subjects, although
this was not statistically significant (P = 0·23). Very low or
undetectable numbers remained so during follow-up, while
higher numbers persisted and sometimes increased after
start of treatment (shown for fast and slow responders in
Fig. 5c); the highest recorded was 20·3% at week 1.
Differences between treatment response groups
When percentages and absolute numbers of each cell type at
diagnosis in fast responders were compared to those at diag-
nosis of slow responders with a Mann–Whitney test, the per-
centages and absolute counts of CD3dim/CD56+ NK T cells at
diagnosis were the only parameters that correlated signifi-
cantly with treatment response − they were significantly
higher at diagnosis in fast responders (P = 0·01, Fig. 5b). The
percentages of CD3dim/CD56+ NK T cells did not change sig-
nificantly during follow-up and are shown for the fast and
slow responding patients in Fig. 5c.
As the CD3dim/CD56+ NK T cell numbers at diagnosis did
not correlate with treatment response in all patients, we used
a multivariate classification technique to find combinations
of variables that may classify patients more accurately into
fast and slow responders. Differences between early response
phenotypes were most prominent at diagnosis and the vari-
ables at diagnosis that were used for the analysis were the
absolute numbers of leucocyte, lymphocyte and T cell sub-
sets. In the support vector machines discriminant analysis
the best classification of patients into the two treatment
response groups could be obtained with just two variables:
absolute CD3dim/CD56+ NK T cells and absolute NK cells
which correctly classified all 13 slow responders and five of
eight fast responders in a leave-one-out cross-validation.
CD3dim/CD56+ NK T cells produce IFN-γ and IL-4
To assess functional aspects of CD3dim/CD56+ NK T cells we
analysed flow cytometric data of intracellular IFN-γ and IL-
4 measurements in saponin-permeabilized T cells after a 4-h
stimulation of whole blood with anti-CD3 antibody. In sam-
ples from patients with a prominent CD3dim/CD56+ NK T
cell population, these cells are found in the CD3-PerCP
Fig. 3. Absolute T cell subset counts of healthy control subjects and 
tuberculosis (TB) patients, calculated from the absolute T cell counts 
and the percentages of the subsets determined by flow cytometric 
immunophenotyping. (a) CD4+ T cells, (b) CD8+ T cells, (c) γδ T cell 
receptor (TCR+) T cells, (d) CD3bright/CD56+ natural killer (NK) T cells. 
Box and whisker plots and statistical analyses as for Fig. 1 (Mann–
Whitney test *P < 0·05, **P < 0·01, ***P < 0·001, Dunn’s post-test 
#P < 0·05, ##P < 0·01, ###P < 0·001).
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versus side scatter plots used for gating the T lymphocytes.
The CD3dim and CD3bright cells were analysed separately. IFN-
γ was only produced by some patients and the CD3dim and
CD3bright cells produced comparable low levels of this cytok-
ine. All patients showed IL-4 production by both stimulated
and unstimulated T cells and this tended to be higher in
CD3dim T cells (Fig. 6). The CD3dim population contains
more cells that express active caspase 3, an indicator of apo-
ptosis, and this expression correlates with higher levels of
intracellular IL-4.
Discussion
In this study we have shown significant changes in absolute
numbers of neutrophils, monocytes and lymphocyte subsets
during active TB. Our finding that these changes occur
already during the first weeks of treatment is important, as it
suggests strongly that TB patients tested at different time-
points during their treatment should not be grouped
together in the analysis of results. We detected a CD3dim/
CD56+ subset of NK T cells that is more prominent in TB
patients and correlates with a faster treatment response. A
multivariate classification technique identified CD3dim/
CD56+ NK T cells, in combination with NK cells, at diagnosis
as variables indicating the likelihood of culture conversion
early during TB treatment. NK T cells have, to our
knowledge, not been reported in the context of TB disease
and we believe that our findings support the future inclusion
of these cells in the search for surrogate markers for treat-
ment response.
The interesting subset of NK T cells found in this study
expressed CD56 and reduced levels of CD3 and was either
double-negative (DN) or weakly CD8+. NK T cells, which
express CD3 and to a variable degree the NK cell markers
CD56, CD57 and CD161 [16–18], are a heterogeneous pop-
ulation in mice and humans with several subsets that differ
in phenotype, TCR repertoire, MHC restriction and cytok-
ine profile, as reviewed in [18]. ‘Classical’ NK T cells express
an invariant T cell receptor (TCR) with Vα24 (Vα14–Jα281
in the mouse, now Vα14–Jα18), are CD1d restricted and
express the NK cell marker CD161 or NKR-P1A. Two subsets
of non-classical NK T cells do not express this invariant TCR.
Human CD56+ NK T cells are abundant in the liver, are pre-
Fig. 4. A representative lymphocyte subset analysis of flow cytometric 
data from a patient with a prominent CD3dim/CD56+ natural killer (NK) 
T cell population. (a) Gating of the CD45bright low side scatter total 
lymphocyte population; (b,c,d) the gated lymphocytes analysed for CD3 
and CD4, CD8 and CD56 expression, respectively. Region R2 in (d) 
contains the CD3dim/CD56+ NK T cells.
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Fig. 5. CD3dim/CD56+ natural killer (NK) T cells. (a) Percentages in the 
lymphocyte gate in controls and patients at diagnosis compared with 
the Mann–Whitney test. (b) Percentages in the lymphocyte gate in 
patients at diagnosis grouped into slow responders to treatment [cul-
ture(+) at week 8] and fast responders [culture(–) at week 8], compared 
with the Mann–Whitney test. (c) Mean percentages of CD3dim/CD56+ 
NK T cell counts with s.d. error bars in the slow and fast responder 
patient groups from diagnosis to end of treatment.
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dominantly CD8+ or DN and Vα24 TCR-negative, have cyto-
toxic capacity and produce Th1 and Th2 cytokines when
stimulated in vitro [19].
As our detection of the CD3dim/CD56+ NK T cells was
unexpected, a Vα24 antibody was not included routinely in
our panel, but some additional phenotypings with this anti-
body indicated that these cells did not express the invariant
TCR (not shown). The possibility of artefactual CD3dim
staining of NK cells due to non-specific binding to Fc
receptors must be considered but this is unlikely, as all the
antibodies used were of the IgG1 isotype and the CD3dim cells
would be double-labelled with the CD4, CD19 and γδTCR
antibody as well, which was not the case and, furthermore,
NK cells do not express the high affinity Fcγ receptors CD32
and CD64 and can be seen as a clearly CD3-negative popu-
lation in Fig. 4d.
The reduced expression of CD3 could be the result of TCR
down-regulation [20] and the CD3dim/CD56+ NK T cells
could be an activated subset of CD3bright/CD56+ NK T cells,
but we found only a weak inverse correlation between the
percentages of these NK T cell subsets (Spearman’s correla-
tion coefficient −0·34, not shown). Takayama et al. [21]
demonstrated that a CD122+ subset of human CD8 T cells
with intermediate TCR expression in the peripheral blood
produce high levels of IFN-γ and are also potently cytotoxic.
Peripheral blood CD56+ T cells are increased during the
early phase of Plasmodium falciparum or P. vivax infections
in humans [22], suggesting an important role in the immune
response to intracellular pathogens. Slifka et al. [23] found
that 90% of virus-specific CD8+ and CD4+ T cells from
choriomeningitis virus-infected mice co-express one or
more NK cells markers for more than 500 days post-
infection. In our patients we did not detect much variation
in the percentages of CD3dim/CD56+ NK T cells over time and
they could represent a similar persistent population specific
for mycobacterial antigens.
Our observation of the often higher numbers and percent-
ages of CD3dim/CD56+ NK T cells in patients indicates that
this cell population is expanded in the blood of some TB
patients, and that these patients are able to clear the infection
more efficiently after the initiation of chemotherapy. As
CD3dim/CD56+ NK T cells appear to produce variable IFN-γ
and IL-4, we postulate that they are cells that have been acti-
vated, as could be indicated by their reduced CD3 expres-
sion, and are at variable stages between activation and
apoptosis. This is supported by our finding that they contain
a higher percentage of cells expressing active caspase 3 and
that they produce more intracellular IL-4. Previous findings
have associated intracellular IL-4 expression in lymphocytes
with mitochondrial apoptosis markers [24]. Therefore
CD3dim/CD56+ NK T cells could be indicators of an active
immune system in TB patients and would accelerate clear-
ance of the infection by antibiotics.
The other variable that, together with CD3dim/CD56+ NK
T cells, had predictive value according to our multivariant
discriminative analysis, was the absolute NK cell count.
Interestingly, a higher NK cell count is partially indicative of
a slow response to treatment. A higher NK cell count in the
peripheral blood may be the result of an inability of these
cells to migrate into infected tissues. In humans NK cells are
present in tuberculous pleural effusions [25], and in mice
infected with Mtb NK cell numbers in the lung increase over
the first 21 days of infection, although their removal does not
Fig. 6. Intracellular cytokine analysis of saponin-permeabilized lym-
phocytes from whole blood of two patients at diagnosis incubated for 
4 h with or without stimulation with 0·1 µg/ml anti-CD3. (a) Gating of 
CD3dim (R1) and CD3bright (R2) T cells in a CD3-PerCP versus SSC plot. 
(b–e) Histograms of the gated cells of one patient showing IFN-γ (b,c) 
and interleukin (IL)-4 (d,e) expression. Overlaid histograms are: (–) 
stimulated, specific antibody, (···) unstimulated, specific antibody, (---) 
stimulated, control antibody. (f–g) Dot plots of similarly gated unstim-
ulated T cells from another patient showing co-expression of caspase 3 
and IL-4. The position of the quadrant markers was determined by a 
phycoerythrin-labelled control antibody (not shown).
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affect host resistance. A role of NK cells in the control of TB
has been suggested by the results of in vitro studies with
human NK cells and Mtb-infected monocytes [26–28].
Monocytes/macrophages are important components of
the innate immune response to mycobacterial infections and
the dramatic change in the absolute monocyte counts in our
patients between diagnosis and week 26 should be noted.
The surprising finding here is that their numbers are signifi-
cantly depressed in fully treated patients and it is unknown
what causes this depressed absolute monocyte count.
To determine whether the depressed absolute monocyte,
NK cell and CD3bright/CD56+ NK T cell counts at the end of
treatment could contribute to increased susceptibility to TB
relapse [10], phenotyping needs to be performed on larger
numbers of blood samples taken after cessation of antibiotic
treatment with subsequent long-term clinical follow-up.
A drawback of our study is that the patient numbers in the
two treatment response groups are small and therefore the
accuracy of the statistical classifications is limited. It is also not
optimal that in our study, for logistical reasons, the week 26
blood samples were taken on the day of the last dose of anti-
biotics and not after cessation of drug therapy. It is unknown
whether drug treatment directly affects cell counts.
In summary, peripheral blood white cell counts change
rapidly during treatment and some counts at diagnosis hold
promise as surrogate markers of treatment response. Further
prospective studies with larger numbers of patients are now
needed to evaluate the role of immunophenotyping in gen-
eral and of CD3dim/CD56+ NK T cells specifically, including
their functional characterization. The role of these cells in
predicting differential outcomes at month 6 and the devel-
opment of recurrence after cure needs to be assessed.
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